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ABSTRACT 
The need for potent antimalarials to prevent the emergence of drug resistant 
Plasmodium falciparum is urgent. Discovery of novel acridone chemotypes have shown 
promise for a new antimalarial drug treatment. Presently, two acridone chemotypes have 
intrinsic antimalarial potency against chloroquine sensitive and multidrug resistant 
parasites. Acridones lacking an N10 side chain are known as chemotype I acridones, 
whereas, chemotype II acridones are defined as having an alkyl side chain at the same 
position. The N10 substitution of chemotype II acridones is thought to target heme and 
inhibit hemozoin formation within the parasite’s digestive vacuole, and is known to 
provide synergistic effects with other antimalarials such as quinine. Currently, the 
molecular target(s) of chemotype I acridones are unknown; therefore, we sought to 
identify the target of these acridones. Using the chloroquine resistant P. falciparum Dd2 
line and the chemotype I compound, T13, we selected stable chemotype I acridone 
resistance by using multiple rounds of 24 hour intermittent pressure and incremental 
continuous pressure. Control parasites exhibited an IC50 value of ~40 nM T13, while 
cloned resistant parasite lines showed IC50 values of ~1300-1700 nM T13. Cross-
resistance was seen with other chemotype I acridones, but not chemotype II acridones, 
indicating the importance of the N10 substitution in avoiding the resistance mechanism. 
Slight cross-resistance to atovaquone and ELQ-400 was seen in T13-resistant parasites, 
indicating that T13 may target the component of the electron transport chain pathway that 
inhibits the binding of ubiquinone to cytochrome b. Two previously reported mutations 
have been identified in the QO site of cytochrome b, M133I and V259L, which confer low 
level (IC50 = 242 ± 18 nM T13) and high level (IC50 = 1439 ± 49) T13 resistance, 
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respectively, in vitro. A third, novel mutation has been identified in the QO site, A138T, 
which accompanies the M133I mutation, and confers high-level T13 resistance (1678 ± 
78). Selection of acridone resistance has led to identification of cytochrome b as the main 
target of chemotype I acridones and the mechanism of action within P. falciparum. 
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Introduction 
Malaria is a worldwide burden. In 2013, the World Health Organization (WHO, 
2013) reported 207 million malaria cases and 627 thousand malaria-related deaths. Most 
cases of malaria occur in sub-Saharan Africa where prevalence of antimalarial drug 
resistance is extremely high. However, the first reported cases of resistance to newly 
introduced antimalarials are usually observed in Southeast Asia (Dondorp et al., 2009). 
Due to the emergence of drug resistant parasites to artemisinin (ART) analogs used as 
monotherapies, in the mid 2000s, the WHO recommended implementation of 
combination therapies for treatment of malaria. Although malaria mortality rates have 
dropped 45% since the year 2000, it is still one of the most economically damaging 
parasitic diseases in the world (Centers for Disease Control and Prevention [CDC], 
2012). The high morbidity and mortality rates caused by malaria have contributed to the 
constant impoverished state of many nations, especially in sub-Saharan Africa (White, 
2004). 
 Malaria results from the infection of host erythrocytes by an intracellular 
protozoan parasite of the phylum Apicomplexa, genus Plasmodium. The most lethal of its 
five human-infecting species is Plasmodium falciparum, which is responsible for the 
majority of reported clinical cases and deaths; with over half of those cases seen in 
children under the age of five and pregnant women. The lethal reputation of falciparum 
malaria is attributed to its ability to induce coma, severe anemia, respiratory distress, and 
cause cytoadhesion of infected erythrocytes (CDC, 2012; WHO, 2013). P. falciparum is 
also well known to become multi-drug resistant (MDR) (White, 2004). The cause of drug 
resistance are single nucleotide polymorphisms (SNPs) within genes such as pfcrt, cytb, 
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pfdhfr, the recently discovered K13, as well as mutations and alterations in pfmdr1 gene 
copy number (Echeverry et al., 2007; Korsinczky et al., 2000; Peterson et al., 1990; 
Ariey et al., 2014; Price et al., 2004). 
Plasmodium falciparum 
Malaria undergoes both a sexual and asexual lifecycle, where two hosts are 
necessary for successful transmission and replication (Figure 1). Transmitted by the 
female Anopheles mosquito, malaria infects not only humans, but other vertebrates as 
well. P. falciparum infection in humans begins as the mosquito takes her blood meal, 
injecting sporozoite-containing saliva into the host. Sporozoites travel to the liver where 
they invade hepatic cells. Within the liver, Plasmodium spp. undergo their first round of 
asexual reproduction through schizogony, resulting in newly formed merozoites capable 
of infecting erythrocytes. 
About 14 days after the asymptomatic liver stage, the merozoites burst from 
hepatocytes and enter the host bloodstream, invading erythrocytes. Here, they undergo 
three developmental stages; the ring stage, the metabolically active trophozoite stage, and 
the schizont stage, where the newly formed merozoites prepare to invade other 
erythrocytes. At the end of P. falciparum’s 48-hour intraerythrocytic developmental 
cycle, the newly formed merozoites (ranging from 8-32) rupture the erythrocyte and enter 
a new, uninfected erythrocyte. The rupturing of the erythrocyte is responsible for clinical 
symptoms such as fever and chills (Cowman et. al, 2012).  
Some of the merozoites that invade erythrocytes develop into macro- and 
microgametocytes which, when ingested by the Anopheles mosquito, undergo sexual 
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reproduction, allowing the transmission of malaria to persist (CDC, 2012). All 
antimalarials used clinically, with the exception of liver stage-targeting primaquine, 
target the intraerythrocytic stage (CDC, 2012). 
 
Figure 1: Life cycle of Plasmodium falciparum. Image taken from Pasvol, 2010. 
 
Antimalarial Combination Therapy  
MDR forms of P. falciparum can survive treatment of some of the most widely 
used and potent antimalarials (Cheeseman et al., 2012). In order to combat MDR malaria, 
patients are given chemotherapies that combine more than one antimalarial drug. The 
most commonly used multi-drug treatments for malaria are the ART-based combination 
therapies (ACTs), which combine a highly potent, short half-life artemisinin analog with 
a longer acting partner drug to clear malarial parasites (White & Olliaro, 1996). The 
utilization of two antimalarials allows for a greater likelihood of complete removal of 
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malaria from the patient (White & Olliaro, 1996). Although this method of malaria 
treatment has proven highly effective, there is a constant concern with the possibility of if 
and when parasites become resistant to the combination therapies used. In combination 
therapy, the shorter acting, highly potent antimalarial rapidly kills the majority of 
parasites, while the second antimalarial, with a longer half-life, acts upon the last 
surviving parasites after cessation of treatment (Figure 2; Nosten & White, 2007). 
However, there are cases where parasites may recrudesce after treatment has been 
administered, due to the ability of surviving the low levels of the second drug in the 
patient. Another concern regarding the low levels of drug is the instance of new 
infections occurring during this period of drug treatment, allowing newly infecting 
parasites to survive and adapt to the drug at tolerable levels (White, 2004). To maintain 
the effectiveness of combination therapy and malaria treatment, as well as possibly 
circumvent the phenomenon of drug resistance, identification of new and potent 
antimalarials are needed.  
 
Figure 2: Proposed mechanism of ACTs and parasite clearance. ART serves to kill the majority of malarial 
parasites while the partner drug serves to protect ART as well as to kill the remaining parasites. Image 
adapted with permission from Philip J. Rosenthal (UCSF). 
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pfcrt and pfmdr1: Markers of Resistance 
In the late 1940’s, chloroquine (CQ) was the first-line antimalarial and cheapest 
treatment available for uncomplicated malaria; however, widespread resistance followed 
in the late 1950s and early 1960s, first arising in the Cambodia-Thailand border and 
Colombia. In the 1960s, resistance spread across South America and Asia, and by the late 
1970s, resistance spread to Africa, which led to the abandonment of CQ as an 
antimalarial in malaria endemic countries (Figure 3; Payne, 1987; Wellems & Plowe, 
2001). The emergence of CQ resistance occurred in several distinct foci over the 30-year 
span. The long period of time it took for resistance to appear indicates the genetic 
complexity of resistance and is consistent with the rarity of emergence (Wellems & 
Plowe, 2001). The wide CQ susceptibility variations of P. falciparum resulted in the 
classification of parasites as “mutant”, or CQ-resistant (CQR), and “wild-type”, or CQ-
sensitive (CQS). CQR is conferred by mutations seen in pfcrt (Plasmodium falciparum 
chloroquine resistance transporter), the gene that encodes for a putative transport protein 
responsible for the efflux of CQ out of the parasite digestive vacuole (DV) (Cooper et al., 
2002; Ecker et al., 2012; Fidock et al., 2000; Sidhu et al., 2002). The most studied pfcrt 
SNP in codon 76 results in replacement of lysine (K) with a threonine (T); this mutation 
is seen in parasites not only resistant to CQ, but other antimalarials as well (Johnson et 
al., 2004; Ecker et al., 2012). Multiple polymorphisms in pfcrt are needed for a parasite 
to become CQR; however, only the K76T point mutation has been universally found in 
CQR lab and field isolates (Cooper et al., 2005). Point mutations in genes such as pfcrt 
and pfmdr1 can completely change parasite susceptibility to antimalarials (Cooper et al., 
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2002; Price et al., 2004). Polymorphisms within pfcrt serve as causal markers of 
resistance to multiple antimalarials.  
 
Figure 3: Foci of CQ resistance emerging as independent events in South America and Asia in the late 
1950s. Resistance spread from Asia to Africa in the 1970s and by the 1980s it had spread  throughout Africa 
(Wellems & Plowe, 2001). 
 
Initially, evidence suggested that point mutations and amplification of 
Plasmodium falciparum multidrug resistance 1 gene (pfmdr1), encoding a P-glycoprotein 
homolog localized on the parasite’s DV membrane, was a key contributor to CQR (Foote 
et al., 1990; Cowman et al., 1991). However, a genetic cross, performed by Wellems et 
al. (1990), showed that pfmdr1 was not responsible for CQ efflux nor was it the key gene 
responsible for CQ resistance in the progeny. Copy number changes and point mutations 
in pfmdr1 have shown to modulate parasite drug susceptibility to multiple antimalarials; 
however, pfmdr1 confers resistance to one drug, mefloquine (MEF) (Smrkovski et al., 
1982; Price et al., 2004).  
Another antimalarial effective in both CQS and CQR parasites is the quinoline 
amodiaquine (AQ). AQ is a currently recommended partner drug in ACT treatment of 
7"
uncomplicated malaria (Olliaro et al., 1996; Rosenthal, 2013). Used as a monotherapy, 
resistance to AQ is likely and is therefore paired with the artemisinin derivative 
artesunate. Parasites resistant to CQ are cross-resistant to AQ in vitro and ex vivo (Olliaro 
et al., 1996; Happi et al., 2006). AQ is an analog of CQ and may possibly have the same 
or similar modes of action; therefore, pfcrt and pfmdr1 mutations seen in CQR parasites 
resulted in decreased susceptibility to AQ and its metabolite monodesethyl amodiaquine 
(Sidhu et al., 2002; Happi et al., 2006; Echeverry et al., 2007). 
Atovaquone  
The only antimalarial currently in clinical use that targets the P. falciparum 
mitochondrial electron transport chain (ETC) is the hydroxynapthoquinone atovaquone 
(ATQ). Developed in the 1990s to combat malaria, resistance to this drug was rapidly 
selected when used as a monotherapy (Looareesuwan et al., 1996). However, when used 
in combination with the antimalarial proguanil, it serves as an effective partner drug in 
prophylaxis and treatment of malaria (Looareesuwan et al., 1996; Gassis & Rathod, 
1996; Srivastava & Vaidya, 1999; Painter et al., 2007). ATQ directly affects the ETC by 
targeting the cytochrome bc1 complex (Complex III) and collapsing the mitochondrial 
membrane potential (Fry & Pudney, 1992; Srivastava, et al., 1997, 1999). Korsinczky et 
al. (2000) found a Y268S mutation (A to C mutation at nucleotide 803) and a M133I 
mutation (nucleotide 399 G to A mutation) in the protein sequence of cytochrome b 
(CYTb) that conferred ATQ resistance in P. falciparum. The mutations were found 
within the QO site of the cytochrome b gene (cytb), where ubiquinol is reoxidized to 
ubiquinone (Figure 4). The QO site is a putative binding region for ATQ within cytb, 
found to have a highly conserved motif in amino acid residues around positions 120-150 
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and 260-280. This also encompasses the well-conserved PEWY motif, which corresponds 
to a critical binding location of ATQ (Korsinczky et al., 2000; Valliéres et al., 2013).  
The Electron Transport Chain 
Within the ETC, ubiquinone, or Coenzyme Q (CoQ), serves as an electron carrier, 
moving through the ETC complexes while generating a protonmotive force (Figure 4a; 
Vaidya & Mather, 2009). Of the four complexes (including ATP synthase) present in 
Plasmodium spp., Complex III is the most critical component of the ETC. Here, CoQ is 
reduced to ubiquinol in the Qi site and re-oxidized back into CoQ by the QO site (Figure 
4b; Vaidya & Mather, 2009). The re-oxidized CoQ leaves Complex III via cytochrome c 
(CYTc), which serves as the carrier from Complex III to Complex IV. As CoQ travels 
through Complexes II, III, and IV, five dehydrogenases aid in supplying electrons to the 
ETC (using CoQ). The most important of these is dihydroorotate dehydrogenase 
(DHODH). This enzyme catalyzes the conversion of dihydroorotate to orotate, which 
serves as the only source of the precursor for pyrimidine synthesis. Malaria parasites are 
unable to salvage pyrimidines; consequently, the role of DHODH is crucial to parasite 
survival (Painter et al., 2007). Without a functional ETC, the parasites die; therefore, the 
ETC is a highly sought after target in drug discovery and synthesis (Vaidya & Mather, 
2009; Barton et al., 2010).  
The mitochondrial DNA (mtDNA) of Plasmodium spp. is a very short, highly 
conserved 6 kb long tandemly arranged DNA segment (Vaidya et al., 1987, 1989). The 
mtDNA does not contain introns and encodes only three proteins, the cytochrome oxidase 
proteins COX1 and COX3, and cytochrome b (CYTb), as well as some fragmented 
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rRNA, while the rest of this pathway is encoded by nuclear DNA (Vaidya & Mather, 
2009). The P. falciparum mitochondria does not contribute much to the ATP pool, as is 
seen in humans, but serves more as an electron disposal system for DHODH, the fourth 
enzyme in the ETC (Srivastava et al., 1997). This may be due to the ETC lacking a 
complete ATP synthase complex needed for maintaining the membrane potential. 
Although DHODH is essential to Plasmodium spp., Painter et al. (2007) replaced 
the ubiquinone-dependent DHODH with a yeast ubiquinone-independent DHODH 
through transfection. In many bacteria, DHODH is independent of CoQ, utilizing 
fumarate instead of ubiquinone as an electron acceptor. Painter et al. (2007) found that 
the DHODH transgenic parasites were no longer sensitive to ATQ and that pyrimidine 
synthesis and membrane potential generation could continue in the presence of CYTb 
inhibitors. The discovery of functional parasites with an independent DHODH and the 
identification of the critical role of this dehydrogenase for parasite survival indicates that 
the ETC could essentially cease to exist in P. falciparum with an independent DHODH, 
thus making this enzyme in the ETC an attractive target for drug therapy. 
Hydroxynapthoquinones, acridones, acridines, quinolones, and pyridones are five 
classes of antimalarial compounds proposed to target the ETC and are currently being 
studied as potential antimalarial treatment and prophylaxis (Kelly et al., 2009; Vaidya & 
Mather, 2009; Barton et al., 2010). From this group, we study the antimalarial effects of 
acridones, which have shown promise as antimalarial treatment for malaria. 
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b.
 
Figure 4: The electron transport chain in Plasmodium falciparum. a) Electrons flow from Complex II 
through IV in the ETC via ubiquinone (CoQ). CoQ reduction occurs by various dehydrogenases embedded 
within the mitochondrial membrane, specifically, DHODH, which is the essential enzyme in this process. 
b) Complex III serves to reoxidize ubiquinone as well as transfer electrons to CYTc, which results in the 
transfer of protons across the membrane, thus creating an electrochemical gradient. 
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Acridones 
Acridones are based on the organic compound known as xanthone, which 
possesses anti-malarial abilities characteristic of its tricyclic structure (Figure 5; 
Ignatushchenko et al., 2000; Kelly et al., 2002). Improvements to the xanthone structure 
by the addition of alkyl side chains with terminal amines at positions 3 and 6 improved 
heme affinity and inhibition of parasite hemozoin formation. The newly synthesized 
xanthone derivatives were highly potent against CQS and CQR P. falciparum parasites in 
vitro, showing 50% inhibitory concentrations (IC50) in the low nanomolar range (Kelly et 
al., 2002). To make a more potent antimalarial similar to xanthones, Winter et al. (2006) 
synthesized haloalkoxyacridones, which possess the tricyclic xanthone mainframe, but 
replaced the oxygen with nitrogen at the 10th position (Figures 5-6). Synthesizing 
haloalkoxyacridones was a fortuitous discovery, as this compound was an intermediate 
during the process of synthesizing acridones with combined antimalarial ability and 
resistance-reversal activity that targeted heme. The chemical intermediate found 
possessed distinctly potent antimalarial activity in vivo and in vitro, but the drug target 
was different than the original acridones synthesized (heme targeting) and was therefore 
termed chemotype I acridones. Chemotype I acridones are dual-stage, broad-spectrum 
antimalarials shown to be effective against both blood and liver stage malaria, but little is 
further known about this compound. However, previous reports suggest that chemotype I 
acridones may inhibit the CYTb complex because of the inhibitory effects studied in beef 
heart mitochondria and the photosynthetic bacteria Rhodospirillum rubrum (Oettmeier et 
al., 1994a, 1994b; Winter et al., 2006).  
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In 2007, Kelly et al. found that xanthones could be further modified to create a 
more potent molecule to combat malaria infection. Changing a xanthone to an acridone 
facilitated the antimalarial potency and supported their aim to combine two drug design 
strategies; the development of a tricyclic heme targeting molecule possessing antimalarial 
abilities, as well as a molecule with resistance reversal activity to re-sensitize parasites 
resistant to quinolines such as CQ. The goal was to synthesize an antimalarial that allows 
for the reintroduction of CQ and possibly serve as a partner drug in combination 
therapies.  
 
Figure 5: Chemical structure of xanthone. 
Further work with acridones by Kelly et al. (2007, 2009) found that the addition 
of an alkyl side chain to the nitrogen at the 10th position on the tricyclic core furthered 
antimalarial abilities. This addition was key to the acridone resistance reversal activity, or 
chemosensitization, as well as digestive vacuole targeting (Figure 6). Chemotype II 
acridones are known to target the parasite digestive vacuole, where the drug can inhibit 
hemozoin formation (Kelly et al., 2007, 2009). Kelly et al. (2009) confirmed chemotype 
II acridones target the DV by finding a decrease in hemozoin production when the 
parasites were exposed to a chemotype II analog both in vivo and in vitro, as well as by 
confocal microscopy, revealing the accumulation of chemotype II acridones in the DV. 
Chemotype II acridones are also synergistic with quinolines such as CQ, piperaquine 
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(PIP) and quinine (QN), and are also seen effective in CQR parasites. Altogether, 
intrinsic antimalarial abilities and chemosensitization, created by the N10 side chain, 
formed a highly potent, dual-functioning acridone. 
 Acridones were previously studied for their abilities to treat multiple diseases 
such as cancer, viral infections, and multiple parasitic diseases (Fujioka et al., 1989; 
Winter et al., 2006). Acridones may represent a new, highly potent antimalarial, more 
potent than quinolines and ATQ (Winter et al., 2006; Kelly et al. 2007, 2009), which 
targets a critical process within P. falciparum. Introduction of acridones into the clinical 
setting may result in the reintroduction and sustained effectiveness of old and new 
quinoline antimalarials.  
 
 
Figure 6: General chemical structure of antimalarial acridones. Dual-stage chemotype I acridones, outlined 
in red, have nitrogen at the 10th position of the tricyclic mainframe and a side chain at the 6th position for 
drug uptake and stability. An electron withdrawing substituent (chlorine) is placed at the 3rd position. In 
chemotype II acridones, the N-10 position has a side chain that allows for acid-trapping, 
chemosensitization, and targeting the DV. 
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Hypothesis and Rationale: 
 Proper functioning of P. falciparum’s ETC to synthesize pyrimidines and create a 
membrane potential is essential for parasite survival (Srivastava et al., 1997; Painter et 
al., 2007). Halting this process through the inhibition of cytb gene results in the collapse 
of the electrochemical proton gradient. Acridones are thought to target CYTb, thus 
resulting in parasite death; nevertheless, the acridone target has not been demonstrated in 
P. falciparum (Oettmeier et al., 1994b; Winter et al., 2006).  
The goal of our study was to identify molecular targets of chemotype I acridones 
in P. falciparum. We hypothesized that selection of acridone resistant parasites in vitro 
would allow us to identify these molecular target(s). To test our hypothesis, we selected 
drug resistant P. falciparum parasites to chemotype I acridones, investigated the structure 
activity relationship (SAR) of chemotype I and II acridones, verified the gene target of 
chemotype I acridones, and determined the relative cost-of-fitness of acridone resistance 
in parasites. 
 
 
 
 
 
 
15"
Methods and Materials 
Culturing 
P. falciparum was cultured by modified methods of Trager and Jensen (1976) in 
either AB+ or O+ human red blood cells (BioChemed Services; Winchester, VA) in 
complete medium consisting of RPMI 1640 (Cellgro; Manassas, VA), 0.5% Albumax I 
(Life Technologies; Carlsbad, CA), 29.8 mM sodium bicarbonate, 25 mM HEPES, 0.37 
mM hypoxanthine, and 0.01 mg/ml, and gentamicin sulfate (MP Biomedicals; Solon, 
OH). Packed red blood cells underwent differential centrifugation and were washed three 
times with RPMI to remove the buffy coat. Cultures were maintained at 37°C under a gas 
atmosphere of 5% O2, 5% CO2, and 90% N2. Parasite cultures were monitored by light 
microscopy at 100x oil with Giemsa-stained (Sigma-Aldrich; St. Louis, MO) thin blood 
smears. All parasite strains used in the selection assays, unless otherwise stated, had no 
previous exposure to T13. CQR P. falciparum lab strain Dd2 was provided by Dr. 
Thomas Wellems (NIAID, Rockville, MD).  
Selection of T13 Resistant P. falciparum Parasites  
(a) 24-h On-off Pressure: 
Parasites of the CQR Dd2 line, standardized to 2% parasitemia and 5% 
hematocrit, were exposed to sequential 24-hour exposures to T13, with increasing drug 
concentration increments at each 24-hour selection. Drug-pressured parasites were 
maintained in either a 50 mL or a 25 mL culture volume. The 24-hour on-off selections 
were performed with 3 independent cultures. A Dd2 control culture was maintained 
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parallel to the drug exposed cultures for the duration of the selections. At 2% parasitemia, 
Dd2 was exposed to an initial dose of 100 nM T13 for a 24-hour period. At 24-hour 
exposure, cultures were washed free of drug with pre-warmed RPMI and diluted 90% 
with fresh erythrocytes and complete media. All cultures were checked 48 hours after 
drug removal to observe parasite growth. Parasite recovery time was scored as time to ≥ 
2% parasitemia following T13 removal. Once recovered, parasites were exposed to 
stepwise increases in T13 concentration by 100 nM, which continued throughout the 
selection process (Figure 7).  
     (b) Continuous Pressure: 
Dd2 parasites exposed up to 1400 nM T13 in on-off selections that remained T13 
sensitive were subjected to continuous drug pressure, initially at 10 nM T13, maintained 
at 5% hematocrit and initially 1% parasitemia. After observation of healthy parasite 
growth (recovery to 1% parasitemia) for at least three 48-hour life cycles, T13 
concentration was increased in 10 nM increments until 100 nM T13, at which point the 
concentration was increased by 100 nM increments until 2200 nM T13, followed by 200 
nM T13 increments until the culture was ended (Figure 7). Throughout the selection, 
drug susceptibility tests were performed to monitor for changes in T13 susceptibility. 
T13-resistant parasites that emerged from drug pressure were cloned according to 
methods by Rosario et al. (1981) and placed into drug susceptibility assays. Genomic 
DNA from resistant and control parasites was extracted and purified with either the 
QIAamp DNA extraction kit (QIAGEN; Redwood City, CA) or ZYMO Quick gDNA 
Miniprep kit (ZYMO Research; Irvine, CA).   
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The continuous selection process was also performed on parasites that did not 
undergo previous 24-hour selection. Wild-type Dd2 parasites were continuously 
pressured for 14 drug cycles, with drug concentrations from 10 nM T13 to 100 nM T13 
(10 cycles), increasing by 10 nM increments. Concentrations of T13 following 100 nM 
were increased by 100 nM increments (4 cycles). An aliquot was taken for cloning when 
resistance was observed, allowing the parasites to continue drug pressure.  
 
 
Figure 7: Stepwise selection of T13-resistant parasites by 24-hour on-off pressure and continuous pressure 
with chemotype I acridone T13. Parasites were pressured incrementally with T13, starting at 100 nM and 
increasing every 100 nM until 1400 nM T13, afterwhich continuous pressure followed starting at 10 nM. 
Parasites were assessed by IC50 and aliquots were taken for cryopreservation throughout the selection 
process.  
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Drug Susceptibility Testing by in vivo and ex vivo Growth Inhibition (IC50) Assays 
Drug stocks were prepared at 10 mM in DMSO, sterile culture grade water, or 
70% ethanol. CQ, ATQ, PIP, MEF, QN, quinacrine (QC), dihydroartemisinin (DHA) and 
lumefantrine (LUM) were purchased from Sigma Aldrich Chemical Co. Chemotype I 
acridones; T2, T2.2, T13, T13M, T14, T17, T19, T20, T22, T26, T27, T31, T35, and T36 
and chemotype II acridones T16.5 and T26.5 were kindly provided by Dr. Jane X. Kelly 
(Portland State University, Portland OR) and endochin-like quinolones (ELQ) 300 and 
400 were kindly provided by Dr. Michael Riscoe (OHSU, Portland OR).   
Drugs were serially diluted in complete media 2-fold across wells 1-10 of a 
Costar® 96 well flat bottom microplate. The last two wells of each row served as drug-
free controls. The initial drug concentration was intended to center the IC50 in the drug 
assay plate. Prior to introduction into the IC50 assay, culture parasitemia was determined 
by Giemsa-stained thin smears and light microscopy from a count of at least 1000 red 
blood cells. Cultures were used in the assay if the parasites were determined to be at least 
60% ring stage. All wells within the IC50 assay plate contained 150 μL of parasite culture 
and 50 μL of drug-containing or drug-free media for a final composition of 0.2% 
parasitemia and 2% hematocrit. Plates were placed in a modular chamber and maintained 
under blood gas atmosphere of 5% O2, 5% CO2, and 90% N2 at 37°C, for 72 hours. For in 
vitro IC50 assays, this method was repeated every 48 hours for at least three independent 
assays, unless otherwise stated.  
IC50 values for standard in vitro cultures was collected using the SYBR Green I 
assay based on previously published methods by Smilkstein et al. (2004). At 72 h (± 2 
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hours), plates were completely frozen at -20°C and thawed immediately prior to 
incubation with SYBR Green I®. 100 μL of the cell lysate from each well was 
transferred to a Costar® 96 well black flat bottom plate, which already contained an 
equal volume (100 μL/well) of SYBR Green lysis buffer (20 mM Tris buffer, 5 mM 
EDTA, 0.008% Saponin, 0.08% Triton X-100, 0.2 μL/mL SYBR Green) at pH 7.4-8.0. 
The lysate-buffer mixture was mixed well under low light conditions and incubated at 
room temperature in the dark for a 1-hour period. Measurement of fluorescence was 
performed with a FLUOstar Omega plate reader (BMG LabTech Inc; Cary, NC) with an 
excitation wavelength set at 485 nm and emission wavelength at 530 nm. Dose-response 
data was fit to a non-linear sigmoidal regression function allowing for a variable slope 
(GraphPad Prism 5.0) to estimate mean IC50 values ± standard error of the mean (S.E.M.), 
which was based on three independent assays. For statistical comparisons, One-way 
analysis of variance (ANOVA) with a Dunnett’s Multiple Comparision test was 
performed on all T13 resistant parasites and Dd2 control. All plates were processed 
within a week after being placed into the freezer.  
For ex vivo studies, P. falciparum samples were collected from children enrolled 
in a longitudinal cohort study for malaria chemoprevention in Tororo, Uganda. Details of 
the study can be found elsewhere (Wanzira et al., 2014). Parasites were placed into a 
single ex vivo drug assay (0.05% parasitemia and 2% hematocrit) within 24 hours after 
removal of parasitized blood from patients and refrigeration at 4°C. The IC50 values were 
collected for CQ and chemotype I compounds T13, T31, and T35. Growth inhibition was 
measured using a histidine-rich enzyme protein 2 (HRP2) based ELISA (Noedl et al., 
2006). Plates used in the ELISA were pre-coated with a primary antibody against 
20"
PfHRP2. The lysed P. falciparum samples were added to the pre-coated plates, incubated 
and washed, and then incubated with the secondary antibody (antibody conjugate of IgG1 
isotype). 3, 3’, 5, 5’-tetramethylbenzidine chromogen (Thermo Scientific; Waltham, MA) 
substrate was added to each well followed by the stopping solution (10% sulfuric acid) 5-
10 minutes later. Absorbance values were collected with a microplate spectrophotometer 
at 450 nm and data was plotted and analyzed with GraphPad Prism 5.0f to obtain IC50 
values. All values were based off a single assay plate per sample. Only data with 
complete sigmodial curves were included in the dataset. 
Whole Genome Sequencing 
Whole genome sequencing of Dd2 control and T13-resistant parasite DNA was 
performed at the University of Notre Dame by Dr. John C. Tan. The sequencing process 
was as follows; 1 mg gDNA was used to generate libraries with the Illumina TruSeq 
DNA library prep kit following manufacturer's instructions. DNA libraries were 
sequenced on an Illumina MiSeq using 250 base pair paired-end reads with a 2% PhiX 
spike-in. The PhiX spike-in served as the sequencing control when libraries were 
generated. Reads were trimmed to remove adapter sequences using Cutadapt v1.2.1 prior 
to read mapping. Reads were aligned to the P. falciparum PlasmoDB v9.3 3D7 reference 
genome using the bwa-mem algorithm of bwa v0.7.5a-r405. varScan v2.3.2 was used to 
identify candidate SNP loci with ≥ 8x read coverage with ≥ 87.5% of the reads 
supporting the SNP genotype. 
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cytb Gene Sequencing 
 DNA extraction with the QIAamp DNA extraction kit or ZYMO Quick gDNA 
Miniprep kit and direct sequencing of the cytb gene was performed on cloned T13 
resistant parasites selected during drug selections 2-4. PCR was performed with primer 1: 
5’-TTCCTGATTATCCAGACGCT-3’ and primer 2: 5’-TGTTCCGCTCAATACTCA 
GA-3’ (Appendix VI), which were designed to amplify the flanking regions of the cytb 
gene. PCR cleanup was performed by enzymatic cleanup with ExoSAP-IT (Affymetrix; 
Santa Clara, CA) or by 1.2% agarose gel electrophoresis, ran at 90V for 50 minutes, and 
QIAquick PCR purification kit (QIAGEN). Internal primer 5’-
CACTCACAGTATATCCTCCACA-3’ was paired with primer 1 and a second internal 
primer 5’-GAGTTATTGGGGTGCAA CTG-3’ was paired with primer 2 for direct 
Sanger sequencing (performed by Genewiz, South Plainfield, NJ). PCR conditions were 
performed starting at 95°C for 2 minutes followed by 30 cycles of denaturing at 95°C for 
30 seconds, annealing at 42°C for 1 minute, and extension at 65°C for 2 minutes. 
Sequences were assembled and aligned with MacVector 9.5.2. 
Determination of pfmdr1 Copy Number  
Copy number of pfmdr1 was assessed by quantitative real time PCR with a Life 
Technologies ViiA7 Real Time PCR System and TaqMan Fast Advanced Mastermix 
following previously published methods (Price et al., 2004). Reactions were performed as 
a multiplex PCR in a MicroAmp 48 or 96 well plate (Life Technologies; Carlsbad, CA). 
Calibration of pfmdr1 copy number was performed with reference strains Dd2, (3 copies) 
(Patel et al., 2010), and CQS 3D7 (1 copy) (Appendix II) (Happi et al., 2009; Ferreria et 
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al., 2006). The pfmdr1 probe was FAM labeled at the 5’ end and β-tubulin was VIC 
labeled (Appendix V). TAMRA served as the 3’ end quencher. The TaqMan Fast 
Advanced Mastermix (Life Technologies; Carlsbad, CA) contained ROX as the passive 
reference dye. Reactions were performed in quadruplicate and assays were repeated if 
data did not conform to exponential kinetics. Data was excluded if threshold values (CT) 
were greater than 36 or if copy number was between 1.3-1.6. Quadruplicate samples were 
run three times for further validation and accuracy. 
Statistical analyses were conducted using GraphPad Prism 5.0f for Mac. The 
distribution of pfmdr1 gene copy number data was found to be non-normal. Data were 
log transformed for determination of significance between control and T13 resistant 
clones by ANOVA using Bartlett’s test of equal variances to evaluate homogeneity of 
variance between groups. Bonferroni Multiple Comparison post hoc tests were performed 
to compare all groups. All tests were conducted using a significance level of 0.05.  
Measurement of Parasite Growth Dynamics 
Dd2-T13 mutant clone and Dd2 control parasite were co-cultured in drug-free 
media to observe the relative fitness of T13 resistant parasites compared to controls 
(Figure 8). Parasites were placed into flasks containing either a 9:1, 1:1, or 1:9 mixture of 
both control and mutant parasites at an initial, total parasitemia of 0.5% (0.25% mutant 
and 0.25% control for 1:1, 0.05% and 0.45% for 9:1 and 1:9). Control and mutant 
parasites were also maintained in separate control cultures. Cultures were synchronized 
using 5% D-sorbitol 48 hours prior to beginning the assay, and a 1500-2000-cell count 
was performed before cultures were mixed. Cultures were maintained in 25 mL volumes 
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at 5% hematocrit and 1-2% parasitemia for ~10 erythrocytic life cycles (20 days). Every 
24 hours (for 1:1 mixtures) and 96 hours, 3 mL aliquots were taken from each culture 
flask, treated with 0.01% saponin and PBS to lyse red blood cells, centrifuged at 3000 
rpm for 7 minutes and washed with PBS. The pellet was stored at -20°C. DNA was 
isolated as described above with a ZYMO DNA kit.  
cytb allele-specific qPCR was used to determine the relative abundance of the 
control vs. mutant parasites. The samples were run in triplicate on a ViiA7 Real Time 
PCR System with TaqMan Fast Advanced Mastermix and TaqMan MGB probes 
(Applied Biosystems; Carlsbad, CA) to observe which parasite predominated in each 
culture by using primers targeting wild-type or mutant cytb. VIC and FAM labeled 
probes allow for distinction between the mutant cytb probe and control cytb probe 
(Appendix VII). Primers used in this assay were common primers; forward (5’ 
TCACATCCTGATAATGCTATCGTAGT 3’) and reverse (5’ GCTGGTTTACTT 
GGAACAGTTTTTAA 3’) while the probes were allele specific. MGB-conjugated 
probes were used to target the wild-type cytb sequence (VIC-CATCTCAAATTGTA 
CCTGAA-MGB) or the mutated sequence (FAM-TACTCCATCTCAAATTTTACCT-
MGB). Standard curves were generated at 1:0, 9:1, 7:3, 1:1, 3:7, 1:9, and 0:1 ratios of 
wild-type:mutant for determination of primer and probe specificity. All 1:1 mixed 
cultures were run in duplicate in three independent competition assays and each DNA 
sample collected was ran in triplicate with the SNP genotyping assay. 9:1 and 1:9 
cultures underwent an independent competition assay and each DNA sample was run in 
triplicate with the SNP assay. 
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Percentages of parasite composition (wild-type vs. Dd2-T13V259L) per day were 
determined by ΔRn mean values. Values were corrected using Dd2 (FAM) or Dd2-
T13V259L (VIC) control’s ΔRn mean value, followed by dividing each mean (1:1, 9:1, and 
1:9) ΔRn value by the corrected control value to obtain the percentage.   
 
 
Figure 8: Competition assay procedure. Dd2:Dd2-T13 flasks were set to 9:1, 1:1, and 1:9 mixtures. DNA 
extraction was performed every two days or four days as well as on the final day (Day 20). SNP genotyping 
was performed with all DNA collected during the 20 day period. At the end of the 20-day period, all 
cultures were placed into a single IC50 assay and cryopreserved.  
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Results  
Generation of in vitro Acridone Resistance in P. falciparum 
Previous studies performed to select drug resistant P. falciparum have utilized 
single step selection or incremental drug pressure (Cooper et al., 2002; Korsinczky et al., 
2000; Witkowski et al, 2009). To investigate the potential for resistance and identify 
mechanisms of resistance in P. falciparum to chemotype I acridones, we utilized an in 
vitro on-off selection technique to select parasites resistant to the chemotype I analog 
T13. T13 resistance was selected in the MDR laboratory strain Dd2; Dd2 is resistant to 
CQ, QN and AQ and has a proclivity for drug resistance, but is sensitive to T13 (IC50 = 
40 ± 5.5 nM). 
In the first selection experiment, 24-hour on-off T13 pressure continued for 81 
days and 14 drug pressure cycles, up to 1400 nM T13, with no resistance detected. The 
culture was split into two flasks, where one continued to undergo 24-hour exposure 
cycles while the other culture was introduced to continuous pressure starting at 10 nM 
T13. The on-off selection continued for another 177 days, at which time T13 
concentration had increased to 3.8 μM (~190-fold higher than Dd2 control IC50); 
however, there was no increase in the T13 IC50 value compared to controls, resulting in 
termination of the culture at this concentration. In contrast, after 65 days (7 drug cycles; 
70 nM T13), resistance was detected in the line that was split off for continuous T13 
pressure. IC50 tests demonstrated a 37-fold shift in IC50, from 40 ± 5.5 nM T13 in controls 
to 1483 ± 73 nM in the resistant line (designated Dd2-T13a). The IC50 results were 
verified with three independent assays after the parasites were pressured at 90 nM T13 
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(Table 1). Seven independent clonal lines were derived from the resistant culture by 
limiting dilution (Rosario, 1981). IC50 assays were performed on three randomly chosen 
clonal lines D1, F1, and H12. All three clones exhibited ~33-39-fold decrease in 
susceptibility to T13 with IC50 values of 1548 ± 26 nM, 1324 ± 49 nM, and 1370 ± 47 
nM, respectively (N = 3, p < 0.05 Dd2-T13 vs. control). 
 
Figure 9: Schematic of selection of T13-resistant P. falciparum. The CQR lab strain Dd2 was used in 
selection experiments. Wild-type Dd2 underwent 24-hour (h) on-off pressure followed by both continuous 
pressure and on-off pressure at 1400 nM T13. Values in boxes indicate T13 IC50 measured from parasites 
under pressure at the T13 concentration indicated above the value. 
 
To attempt selection of additional parasites resistant to T13, we repeated the on-
off experiment with two independent wild-type Dd2 cultures (Dd2-T13b and Dd2-T13c). 
Both Dd2 cultures tested resistant by IC50 after parasites recovered from 1300 nM, 24-
hour T13 pressure, with T13 IC50 values of 1407 nM and 796 nM (N=1) (Table 1). 
However, subsequent cloning resulted in mixed sensitive and resistant parasites. 
Therefore, to kill remaining wild-type parasites, both cultures underwent continuous T13 
pressure from 10 to 20 nM T13 over a period of approximately 3 weeks. Two subsequent 
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clonal lines from Dd2-T13b and Dd2-T13c (clones H9 and D3) had T13 IC50 values of 
1578 ± 79 nM and 1528 ± 70 nM (N = 3; p < 0.0001), respectively (Table 3).  
The days to recovery after each 24-hour drugging cycle in the three independent 
cultures were examined for an association with T13 dose. Following drug washout, the 
T13-pressured Dd2 cultures grew similar to controls (parasitemia ≥ 2% within 48 hours) 
throughout the selection experiment, including T13 doses ~95-fold greater than the wild-
type Dd2 IC50. The average days of on-off recovery for Dd2-T13a, pressured up to 3.8 
μM T13, was 2.4 days (Figure 10). Dd2-T13a parasites recovered at an average rate of 
1.3 days after 24-hour pressure from 100 nM to 600 nM T13. Parasite recovery declined 
slightly during T13 pressure from 700 to 2800 nM, averaging 2.8 days. 24-hour pressure 
from 2800 nM to 3800 nM T13 had a recovery rate of 1.6 days, similar to the initial 
recovery time (data not shown). During on-off pressure in Dd2-T13b and Dd2-T13c, 
average recovery rates up to 1400 nM T13 (35-fold greater than Dd2 IC50) were 2.8 and 
2.9 days, respectively (Figure 10). Bivariate correlation analyses indicated there was no 
association between growth pattern and drug concentration prior to selection of T13-
resistance, suggesting that the parasites remaining in the culture after drug removal and 
90% cut did not die, but instead, recovered. 
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Figure 10: Dd2 recrudescence rates during 24-hour on-off selection. Days to recovery from 100 nM to 
1400 nM T13 for three independent Dd2 cultures that underwent 24-hour on-off pressure. All days to 
recovery values are based on the time it took the culture to reach at least 2% parasitemia after drug 
removal. Each color represents a Dd2 culture. 
 
To determine the stability of the T13 resistance phenotype in long-term culture, 
we cultured clone Dd2-T13H12 in the absence of T13 pressure for 82 days. T13 resistant 
parasites grew at a rate comparable to controls during the period without drug exposure, 
and remained T13 resistant at the end of the experiment when tested by IC50 assay (Dd2-
T13H12 IC50 = 900 nM T13, N = 1).  
We next investigated if T13 resistance could be selected with only continuous 
pressure. A Dd2 culture with no prior exposure to T13 was maintained under continuous, 
increasing T13 pressure for 144 days. This experiment generated parasites with a 
moderate level of resistance compared to earlier resistant lines, with an IC50 of 290 ± 17 
nM (~ 6-fold increase relative to parent line, p < 0.05) following 136 days of pressure and 
drug increased to 500 nM T13 for 18 days (Table 1). Cloning of the T13-resistant culture 
29"
(Dd2-T13d) resulted in recovery of five clonal lines, with IC50 values of 257 nM-337 nM 
T13. Continued drug pressure on Dd2-T13d for 39 days further decreased parasite 
susceptibility, with T13 resistant parasites emerging at 900 nM T13 pressure exhibiting a 
T13 IC50 of 1065 nM (N = 1), similar to T13 resistant parasites selected earlier (Table 1).  
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Table 1: In vitro antimalarial response of pre-clonal T13 resistant P. falciparum cultures Dd2-T13a-d.  
 
Drug 
Parasite line (IC50 in nM) 
Dd2 Dd2-T13a Dd2-T13b Dd2-T13c Dd2-T13d 500 nM 900 nM 
CQ 217 ± 10 208 ± 13 285a 309a 254 ± 8.6 191a 
T13 40 ± 5.5 1483 ± 73**** 1407 796 290 ± 17 ** 1065  
ATQ 0.50 ± 0.07 ------ 3.4 1.7 5.3 ± 0.14*** 1.2  
 
IC50 values ± SEM in nM. N = 3. 72 h microplate test using Sybr Green detection. 
a N = 1 for values without SEM.  
------  IC50 was not taken with the specified drug during this time. 
 
Two-tailed t-test of resistant vs. Dd2 control where p < 0.0001 [****] 
Two-tailed t-test of resistant vs. Dd2 control where p < 0.001 [***] 
Two-tailed t-test of resistant vs. Dd2 control where p < 0.01 [**]
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Whole Genome Sequencing for SNP Identification 
The genomes of two Dd2 control clones, Dd2H5 and Dd2G4, as well as two Dd2-
T13 resistant clones, Dd2-T13aF1 and Dd2-T13aH12, were sequenced by the Illumina 
MiSeq to identify putative single nucleotide polymorphisms (SNPs) associated with T13 
resistance. 15 nonsynonymous SNPs were identified in the coding regions of the Dd2-
T13a parasites genome (Table 2). We have identified a SNP from a G to T amino acid 
change at position 775 in cytb codon 259 that confers a valine (V) to leucine (L) change 
(Figure 11a) in both clonal lines, relative to controls. These results support previous 
observations of acridones targeting CYTb (Oettmeier, 1994b), and therefore were 
considered the most likely cause of T13 resistance in the selected parasite lines. 
Protein sequences from six Plasmodium spp. and three other eukaryotic 
organisms (Toxoplasma, human and chicken) were aligned and compared to the mutant 
clones Dd2-T13aF1 and Dd2-T13a H12. The aligned sequences have a high degree of 
conservation between all species, especially in the 5 different species of Plasmodia. The 
V259L mutation in CYTb was in the highly conserved region of the QO site, specifically 
next to the “pewy” loop, which is conserved across eukaryotic species (Figure 11a; 
Vaidya & Mather, 2009).  
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Table 2: SNPs identified within P. falciparum Dd2-T13aF1 and H12 nuclear and mitochondrial genomes.  
Chromosome Position 3D7 (Ref) Dd2 Mutant Gene Gene Description 
Mitochondrial 4266 (775) G G T mal_mito_3 apocytochrome b (cytb) 
6 629354 A A G PF3D7_0615300 
Conserved Plasmodium 
membrane protein, 
unknown function 
7 1298098 A C A PF3D7_0730300 transcription factor with AP2 domain(s) (ApiAP2) 
7 192738 C T C PF3D7_0704200 
tRNA m5C-
methyltransferase, 
putative 
7 778333 G A G PF3D7_0718000 dynein heavy chain, putative 
8 261401 C A C PF3D7_0804500 
Conserved Plasmodium 
membrane protein, 
unknown function 
8 544091 A A T PF3D7_0810600 RNA helicase, putative 
11 218599 A C A PF3D7_1104900 
Calcium/calmodulin-
dependent protein kinase, 
putative 
11 24858 G C G PF3D7_1100100 Erythrocyte membrane protein 1, PfEMP1 (VAR) 
11 330499 C C T PF3D7_1107800 Transcription factor with AP2 domain(s) (ApiAP2) 
12 1670672 C T C PF3D7_1239800 
Conserved Plasmodium 
protein, unknown 
function 
12 2246731 C C A PF3D7_1255200 Erythrocyte membrane protein 1, PfEMP1 (VAR) 
13 1259510 T C T PF3D7_1329600 
Conserved Plasmodium 
protein, unknown 
function 
14 1225767 T C T PF3D7_1431200 
Conserved Plasmodium 
protein, unknown 
function 
      Conserved Plasmodium  
membrane protein,  
unknown function 
14 1319520 G A G PF3D7_1433400 
      
 
Highlighted rows indicate SNP in T13-resistant mutant differs from both the reference strain (3D7) and the 
parental line (Dd2). Data provided by John C. Tan from University of Notre Dame. 
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cytb Sequencing from additional T13 Resistant Parasites 
To ascertain whether a cytb mutation was the probable source of T13 resistance in 
P. falciparum parasites, Sanger sequencing of cytb was performed with four other 
independently selected T13 resistant parasites. The samples sequenced were eight Dd2-
T13 resistant clones: Dd2-T13bA3 and H9, Dd2-T13c D3 and A2, Dd2-T13dF5 and G9, all 
exhibiting IC50 values greater than 1300 nM T13, and Dd2-T13d clones E4 and H11, 
which produced IC50s of 242 ± 17.6 and 216 ± 14.3, respectively. IC50 values for each 
independent mutant clone have been reported in table 3. Sequence alignment with 
MacVector revealed a common V259L mutation among Dd2-T13a-c parasites with the 
higher level of T13 resistance. All Dd2-T13d clones (F5, G9, E4 and H11) had an M133I 
polymorphism in CYTb (G to T change at nucleotide 399) while retaining the wild-type 
V259. The former mutation is known to play a role in ATQ resistance (Figure 11b) 
(Korsinczky et al., 2000). Dd2-T13d clones F5 and G9 had a secondary G to A mutation 
at nucleotide position 412 (A138T amino acid change), which has not been previously 
reported. 
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a) 
 
       QO site region 2 
 
Dd2-T13a-c  DNAIVVNTYVTPSQILPEWYFLPFYAMLKTVPSKPAG 244-281!
P. falciparum  DNAIVVNTYVTPSQIVPEWYFLPFYAMLKTVPSKPAG 244-281!
P. yoelii yoelii DNAIIVNTYVTPLQIVPEWYFLPFYAMLKTIPSKNAG 244-281 
P. knowlesi   DNAILVNTYVTPIQIVPEWYFLPFYAMLKTIPSKTAG 244-281 
P. chabaudi  DNAIIVNTYVTPLQIVPEWYFLPFYAMLKTIPSKNAG 244-281 
P. vivax  DNAILVNTYVTPIQIVPEWYFLPFYAMLKTIPSKTAG 244-281       
P. berghei  DNAIVVNTYVTPLQIVPEWYFLPFYAMLKTIPSKNAG 244-281 
Toxoplasma  DNSIPVNRFVTPLHIVPEWYFLAYYAVLKVIPSKTGG 240-277 
Human    DHYTLANPLNTPPHIKPEWYFLFAYTILRSVPNKLGG 254-291                  
Chicken  ENFTPANPLVTPPHIKPEWYFLFAYAILRSIPNKLGG 255-291 
b) 
 
QO site region 1 
 
Dd2-T13d  VTAFVGYVLPWGQISYWGATVITNLLSSIPVAVIWIC 120-156 
Dd2-T13d  VTAFVGYVLPWGQISYWGTTVITNLLSSIPVAVIWIC 120-156 
Dd2-T13a-c  VTAFVGYVLPWGQMSYWGATVITNLLSSIPVAVIWIC 120-156 
P. falciparum  VTAFVGYVLPWGQMSYWGATVITNLLSSIPVAVIWIC 120-156 
 
 
Figure 11: CYTb amino acid sequence of Dd2-T13 resistant parasites. a) Dd2-T13a-c resistant clones 
revealed a SNP in cytb corresponding to a V259L amino acid change, lying in or near the QO site region 2 
of the CYTb complex (Valliéres et al., 2013). This SNP differs from mutations seen in ATQ-resistant 
parasites (Korsinczky et al., 2000; Mather, Henry & Vaidya, 2007). b) Dd2-T13d clones revealed a SNP in 
cytb that corresponds to a M133I mutation, lying within putative QO site region 1 of the CYTb complex 
(Valliéres et al., 2013). This mutation was previously reported by Korsinczky et al. (2000) to play a role in 
ATQ resistance. The Dd2-T13d clones also revealed a novel A138T mutation accompanying the M133I 
mutation in QO site region 1.The Dd2-T13d clones did not acquire the V259L mutation. 
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pfmdr1 Copy Number Variation 
pfmdr1 copy number variation is associated with parasite resistance to multiple 
antimalarials, such as CQ, PIP, and MEF (Reed et al., 2000; Eastman et al., 2011; Price 
et al., 2004). Therefore we tested the Dd2-T13V259L mutant parasites for pfmdr1 copy 
number variation by qPCR to identify whether gene copy changes were associated with 
T13 resistance. Three independent analyses for pfmdr1 copy number with three Dd2-
T13a clones (F1, D1, and H12) indicated an increase in pfmdr1 copy number from 3 to 
3.78 (SD = 0.39), 3.76 (SD = 0.42), and 4.0 (SD = 0.23), respectively, when compared to 
the controls 3D7 (N = 1) and Dd2 (N = 3) (Figure 12).  
Bartlett’s test of equal variances indicated that copy number did not differ 
significantly between controls and Dd2-T13 clones (B = 4.91, p = 0.30) and satisfied the 
assumption of homogeneity of variance. A one-way ANOVA indicated that there was a 
statistically significant difference between Dd2 and Dd2-T13 clones pfmdr1 copy number 
(F [4, 55] = 517.6; R2 = 0.97; p < 0.0001). Bonferroni post hoc tests revealed that Dd2 
was significantly less than all three Dd2-T13 clones (p < 0.05). The increase in pfmdr1 
copy number that accompanies CYTb V259L may be a compensatory adaptation related 
to parasite fitness (Price et al., 2004), or the selection of increased copies was due to a 
mixed Dd2 population. 
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Figure 12: pfmdr1 copy number variation. Copy number (CN) analysis of reference strain 3D7 (CN = 1.01, 
SD = 0.04), Dd2 parental (CN = 3.16, SD = 0.18), and Dd2-T13a-resistant clones (CN = 4.0, SD = 0.23; 
3.76, SD = 0.42; and 3.78, SD = 0.39). Samples were run in quadruplicate on a Viia7 Real Time PCR 
instrument (Life Technologies Inc.) for three independent assays. Error bars indicate standard deviation. 
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Structure Activity Relationships of Acridones in T13-resistant P. falciparum 
To determine whether T13 resistance affected parasite susceptibility to other 
chemotype I acridones, we performed growth inhibition assays on a Dd2-T13V259L clone 
against a panel of 13 chemotype I compounds. Chemotype I acridone analogs were potent 
antiplasmodials in vitro against control P. falciparum line Dd2 (Tables 3 and 4), with IC50 
values ranging from 0.29 nM to 616 nM, with six out of the 13 chemotype I acridones 
tested exhibiting IC50 values below 100 nM. All chemotype I compounds, except for 
T2.2, exhibited varying degrees of cross-resistance to T13 in the Dd2-T13V259L parasites, 
with IC50 values 3-fold to 26-fold higher than control values (p < 0.05). Conversely, 
cross-resistance was not observed when Dd2-T13V259L was tested against chemotype II 
acridones T16.5 and T26.5 (Table 3), indicating the importance of the N10 side chain in 
prevention of cross-resistance.  
Chemotype I acridones T2, T14, T26, and T27 have the same alkoxyamine side 
chain as T13 at the 7th position of the acridone core (Appendix III). All 4 of these 
acridone analogs have significantly higher IC50 values in Dd2-T13V259L compared to Dd2 
from 6-fold to 26-fold higher (Table 3). The Cl substituents at positions 2 and 3 on T14 
may be the cause for the lowest fold change in IC50. T19, T20, T31 and T13M have Cl 
substituents at the 1 and 2 positions on the acridone core, as does T13 (Appendix III). 
The four analogs had IC50 values 2.9-10 fold higher than the control, with the highest 
shift from 14 ± 1.4 nM to 140 ± 4.5 nM to T31 (p < 0.0001). The side chain on T31 is the 
most structurally similar to T13, which may be the cause for the highest shift in 
susceptibility from this group. T17 had a 25-fold shift in IC50 from 22 ± 1.5 nM to 551 ± 
13 nM T17 (p < 0.0001), which may result from the Cl substituent at the same position as 
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seen on T13. These results suggest that most of the chemotype I acridones tested have the 
same or similar drug target as T13. 
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Table 3: Structure activity relationship (SAR) of chemotype I and II acridones demonstrate varying 
degrees of cross-resistance in chemotype I acridones when compared to Dd2 control. 
 
Class Drug 
IC50 ± SEM (nM) P. falciparum Index of 
Resistance Dd2 Dd2-T13aF1 
4-aminoquinoline CQ 217 ± 9.9 260 ± 17 1.2 
Hydroxynapthoquinone ATQ 0.50 ± 0.043 4.1 ± 0.15 8.2**** 
Chemotype I Acridone T2 117 ± 12 2122 ± 83 18**** 
 T2.2 366 ± 14 355 ± 7.9 1.0 
 T13 39 ± 1.1 1439 ± 49 37**** 
 T13M 186 ± 7.3 843 ± 31 4.5**** 
 T14 212 ± 7.6 1321 ± 58 6.2**** 
 T17 22 ± 1.5 551 ± 13 25**** 
 T19 390 ± 15 1103 ± 48 2.8** 
 T20 616 ± 17 3113 ± 81 5.1**** 
 T22 139 ± 3.9 2426a 18 
 T26 20 ± 1.6 525 ± 20 26**** 
 T27 31 ± 1.4 668 ± 32 22**** 
 T31 14 ± 1.4 140 ± 4.5 10**** 
 T35 9.0 ± 0.98 216 ± 8.2 24**** 
 T36 0.29 ± 0.030 5.5 ± 0.15 19**** 
Chemotype II Acridone T16.5 231 ± 5.4 248 ± 7.0 1.1 
 T26.5 91 ± 5.5 95 ± 2.2 1.0 
*IC50 values ± SEM in nM. N = 3. 72 h microplate test using Sybr Green detection. 
Refer to Appendix III for structures of antimalarials. 
a Value based on a single assay. 
Two-tailed t-test of mutant vs. Dd2 control where p < 0.0001 [****] 
Two-tailed t-test of mutant vs. Dd2 control where p < 0.01 [**] 
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Drug Susceptibility of cytb Mutants to Other Antimalarials 
 
To test the susceptibility of Dd2-T13 resistant parasites to mechanistically diverse 
antimalarials, we screened the parasites with CQ, QN, MEF, LUM, PIP, DHA, QC, ATQ, 
ELQ-300, and ELQ-400 (Table 4; Appendix IV). The cytb mutants IC50 values presented 
no change in susceptibility except to CYTb QO site targeting antimalarials ATQ and 
ELQ-400. There was an 8.8-fold shift in ATQ IC50 in Dd2-T13V259L mutants (3.8 ± 0.26 
nM) relative to Dd2 (0.43 ± 0.038 nM; p < 0.0001), 17-fold increase in Dd2-T13M133I 
mutants (6.9 ± 0.95 nM ATQ; p < 0.0001) and a 3.3-fold increase in ATQ IC50 to Dd2-
T13 M133I-? (1.4 ± 0.052 nM, p < 0.05). When tested against the QO site targeting 
compound ELQ-400, Dd2-T13V259L mutants exhibited a 10-fold shift in susceptibility 
(Dd2 3.4 ± 0.11 vs. Dd2-T13F1 33 ± 2.2; p < 0.001), while the Dd2-T13M133I mutants had a 
4.7-fold increase in ELQ-400 IC50. However, the Dd2-T13 M133I+A138T mutant had no 
change in ELQ-400 susceptibility (Table 4). The lack of cross-resistance observed in the 
CYTb QI-site targeting ELQ-300 (Stickles et al., 2015a) and cross-resistance in QO site 
targeting antimalarials strongly suggest T13 is also a CYTb QO site targeting antimalarial. 
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Table 4: Drug susceptibility results of cloned P. falciparum Dd2-T13 mutants. 
Drug Dd2 
Dd2-T13 Resistant Mutants; IC50 ± SEM (nM) 
T13V259L  T13M133I T13M133I+A138T 
CQ 181 ± 4.3 166 ± 7.1 182 ± 5.6 186 ± 8.0 
QN 254 ± 9.8 215 ± 7.5 197 ± 3.5 199 ± 13 
MEF 18 ± 1.3 23 ± 0.95 14 ± 0.71 13 ± 0.61 
LUM 5.7 ± 0.21 6.5 ± 0.32 3.6 ± 0.19 3.6 ± 0.26 
PIP 9.0 ± 0.17 7.1 ± 0.25 10 ± 0.31 7.4 ± 0.27 
ATQ 0.43 ± 0.038 3.8 ± 0.26**** 6.9 ± 0.95**** 1.4 ± 0.052** 
T13 40 ± 5.5 1439 ± 49**** 242 ± 18** 1678 ± 78**** 
QC 29 ± 1.3 18 ± 0.74* 23 ± 0.59 29 ± 0.67 
ELQ-400 3.4 ± 0.11 33 ± 2.2*** 0.72 ± 0.035 3.1 ± 0.14 
 
IC50 values ± SEM in nM. N ≥ 3. 72 h Microplate test using Sybr Green detection. 
Parasites with the V259L mutation underwent both 24-hour and continuous pressure. IC50s represent values 
collected from three independent cultures that selected for the V259L mutation in CYTb. Parasites with the 
M133I and M133I+A138T mutation underwent only continuous pressure. 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.0001 [****] 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.001 [***] 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.01 [**] 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.05 [*]
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ex vivo Data Indicate High Potency of Chemotype I Acridones 
Drug sensitivity data was collected from 20 P. falciparum isolates from Tororo, 
Uganda against CQ and chemotype I acridones T13, T31, and T35 in 2013. The 
chemotype I acridones were highly potent against clinical isolates, exhibiting ex vivo IC50 
values similar to in vitro values against lab strain Dd2 (40 ± 5.5 nM T13; 14 ± 1.4 nM 
T31; 9.0 ± 0.98 T35). Table 5 shows IC50 values in median and range due to the 
variability in isolate susceptibility to each antimalarial tested. The maximum IC50 values 
observed in clinical isolates for T13, T31, and T35 were 20-fold, 19-fold, and 9.4-fold 
lower in IC50, respectively, than for the in vitro selected T13 resistant line, Dd2-T13V259L 
(Tables 3 and 5). From the data collected, no clinical isolate appeared resistant to the 
chemotype I acridones tested. 
 
Table 5: ex vivo data collected from P. falciparum Ugandan isolates against CQ and Chemotype I 
acridones. 
ex vivo IC50s from P. falciparum Ugandan Isolates. Median and Range (nM). 
Drug CQ (n = 17) T13 (n = 20) T31 (n = 20) T35 (n = 18) 
Median 124 28 3.4 6.5 
Range 18 – 1152 11 – 72 0.54 – 7.4 2.3 – 23 
 
IC50 values; N = 1. 72 h microplate test using HRP2 ELISA (Noedl et al., 2006). 
n = number of isolates tested per drug. 
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Fitness Cost of the V259L Mutation 
Acquired mutations in drug resistant P. falciparum come at a fitness cost 
(Rosenthal, 2013). Therefore, we hypothesized that the T13 resistant parasites with the 
CYTb V259L mutation would incur a fitness cost relative to the Dd2 control. The long-
term competition experiment with wild-type Dd2 and Dd2-T13V259L was performed for a 
20-day period (~10 generations) in mixed cultures at 1:1, 9:1, and 1:9 ratios. DNA was 
harvested every 48 or 96 hours and culture composition was quantified by TaqMan qPCR 
using probes specific to the wild-type cytb allele (V259) and the mutant cytb allele 
(V259L) to determine allele abundance over time from the mixed cultures. The 
competition experiment was performed three times for the 1:1 mixtures and once for the 
9:1 and 1:9 mixtures. The 1:1 mixed populations became predominantly T13 resistant 
over the 20-day period for all three experiments. In the 1:1 in vitro cultures, the results 
showed that the Dd2-T13V259L line consistently outcompeted the wild-type control. In the 
9:1 culture (90% wild-type to 10% mutant), parasite composition was unchanged by day 
20, with 93% of the culture being wild-type Dd2 parasites. In contrast, the 1:9 culture 
(90% mutant) became 99% Dd2-T13V259L mutant at the end of the 20 days. The single 
IC50 assay ran at the end of the 20-day period for each culture reflected the proportion of 
mutant or wild-type alleles measured by qPCR and the standard curve (Table 6 and 
Figure 13).    
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Table 6: Competition assay IC50 values on day 20-22 and standard curve a. 
Drug 
P. falciparum Standard Curve (IC50 in nM) 
Dd2 9:1 7:3 1:1 3:7 1:9 Dd2-T13V259L 
CQ 166 168 160 158 160 171 175 
T13 27 27 37 641 905 1095 1240 
ATQ 0.29 0.42 0.43 0.49 1.3 2.6 2.7 
 
Drug 
P. falciparum Mixed Ratio Cultures * 
Dd2 Dd2-T13V259L 9:1 1:9 1:1 assay 1 1:1 assay 2 1:1 assay 3 
CQ 252 215 232 225 225 149 223 
T13 40 1056 47 1315 1240 1232 1359 
ATQ 0.23 2.0 0.15 1.1 3.2 2.6 2.2 
* Ratio indicates parasite composition at the beginning of the experiment (Dd2:Dd2-T13V259L). IC50 values represent parasite cultures after  
20-22 days of culturing. 
a IC50 values where N = 1. 
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a) 
 
b) 
 
Figure 13: Dd2:Dd2-T13V259L competition assay results collected by qPCR. a) In all three 1:1 competition 
assays, culture composition shifted from mixed to majority Dd2-T13V259L. b) The culture with majority T13 
mutant (1:9) became fully resistant at the end of 20 days while the culture with majority wild-type Dd2 
(9:1) became sensitive. 
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Discussion: 
The long-term efficacy of antimalarial treatment is of great importance in 
eradicating malaria. Acridones are powerful antimalarial compounds and an attractive 
drug candidate for prophylaxis and treatment of malaria. In murine models, 40 mg/kg of 
T13 prevented development of liver stage malaria, with no parasites visible in the mouse 
24 and 48 hours later (Kelly, J. X., personal communication). Multiple chemotype I 
acridones are reported to be effective antimalarials in vitro and in vivo (Winter et al., 
2006; Kelly, J. X., personal communication). 
Although proper chemotherapy is generally effective in clearing the majority of 
malaria in a patient, the selective pressure created as blood drug levels decrease in 
malaria-infected patients may result in the selection of drug resistant P. falciparum 
(Malmberg et al., 2013). The select few parasites that survive high, lethal doses of drug 
exposure may result in the eventual replication and spread of drug resistant parasites 
(White, 2004). In vitro and in vivo reports of resistant parasites arising from selective 
drug pressure date back to the late 1950s, with the rise of CQ-resistant parasites (Nguyen-
Dinh & Trager, 1978; Payne, 1987). The emergence of resistant parasites by in vitro 
selective drug pressure may occur with both continuous (Korsinczky et al., 2000; 
Johnson et al., 2004) and intermittent exposure (Eastman et al., 2011). 
Acridone Chemotype I (T13) Resistance in P. falciparum  
In this study, we report the in vitro selection of chemotype I acridone T13 
resistance in P. falciparum using the CQR parasite Dd2, originating from Indochina 
(Oduola et al., 1988). MDR Dd2 parasites were selected for the drug pressure study 
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because of their propensity to acquire drug resistance (Rathod et al., 1997). In published 
methods on selecting drug resistant P. falciparum, experiments used incremental, 
intermittent or continuous pressure. Johnson et al. (2004) used intermittent pressure to 
select drug resistant P. falciparum to the antiviral amantadine and antimalarial 
halofantrine (HF), while simultaneously restoring CQ sensitivity, leading to the discovery 
of novel pfcrt mutations involved in antimalarial cross-resistance and the proposal of a 
charged drug leak. Utilization of continuous pressure with spiroindolones derived drug 
resistant parasites after 3-4 months of pressure that suggested the P-type cation-
transporter ATPase4 as the drug target (Rottmann et al., 2010).  
Our study applied 24-hour on-off, intermittent pressure reflective of drug 
exposure and clearance observed clinically in malaria chemotherapy regimens. In a 
murine model, T13 had a half-life of 4.7 hours in plasma and 36 hours in the liver after a 
single dose of 80 mg/kg (Kelly, J. X., personal communication). Using both 24-hour and 
continuous pressure, we selected parasite lines resistant to chemotype I acridone T13 in 
four independent experiments. A single nucleotide change in parasites from three of the 
cultures resulted in a V259L amino acid change in CYTb, while the fourth selection 
resulted in an M133I and A138T double amino acid change in the same protein. These 
mutations correspond to the ubiquinol oxidation site, or QO binding site in CYTb 
(Valliéres et al., 2013). The V259L mutation was recently reported from ELQ-400 
resistant P. falciparum parasites (Stickles et al., 2015b), while the M133I mutation was 
reported from ATQ resistant P. falciparum and P. berghei (Korsinczky et al., 2000; 
Syafruddin et al., 1999); however, the A138T mutation was previously unknown. The 
V259L mutation conferred a higher level of resistance to T13, with IC50 values from 
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1300-1600 nM T13, while M133I conferred lower levels of T13 resistance, with IC50 
values ranging from 200-400 nM. The combination of the M133I and A138T mutations 
resulted in higher levels of T13 resistance compared to the latter single mutant, with IC50 
values from 1300-1700 nM T13. 
Sequencing of cytb in the Dd2-T13M133I+A138T mutant selected in the fourth 
experiment revealed a double mutation in CYTb, the M133I mutation and a novel 
mutation at amino acid position 138, where an alanine was replaced with a threonine. The 
secondary mutation is the most likely cause for the increase in IC50 from ~230 nM T13 to 
values from 1300-1700 nM T13 (Appendix IV), suggesting the mutation further reduced 
binding affinity of T13 to the QO site. It is unknown whether the A138T mutation can 
confer resistance on its own; therefore, this mutation may need to be studied further by 
site-directed mutagenesis or additional selection experiments. The increased 
susceptibility of Dd2-T13M133I+A138T to ELQ-400 and ATQ indicates that the secondary 
mutation provided a better binding site for both antimalarials and suggests that the 
A138T mutation compensated for the M133I mutation, thus resulting in inverse cross-
resistance with T13. Korsinczky et al. (2000) reported the same event in CYTb when 
M133I was found with mutations P275T, K272R, or G280D that conferred 220-, 537-, 
and 897-fold the IC50 of the control parasites, respectively.  
In our first T13 selection experiment, parasites remained sensitive with on-off 
pressure; however, resistant parasites emerged under subsequent continuous pressure. 
The emergence of resistant parasites under continuous pressure was most likely due to 
the resistant parasites not being selected initially during on-off pressure, or perhaps they 
were present during this time, but too low in number to be detected. In the second and 
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third selections, a combination of intermittent and continuous pressure produced 
additional lines of T13 resistant parasites. Although resistant parasites were selected with 
on-off pressure, the following continuous pressure was necessary to allow the T13 
resistant parasites to outcompete the wild-type Dd2. The fourth selection with Dd2 
demonstrated that T13 resistant parasites could be selected using only continuous 
pressure. Altogether, the results indicate there is no pattern associated with drug selection 
strategies because T13 resistant parasites were selected using both methods combined or 
alone. 
The period of time it took to select resistant parasites with T13 is greater than the 
time it took to select ATQ resistant and ELQ-400 resistant parasites. ATQ is known to be 
a highly potent antimalarial; however, ATQ resistance can be rapidly selected when used 
as a monotherapy (Looareesuwan et al., 1996). Rathod et al. (1997) selected ATQ 
resistant P. falciparum parasites in vitro after a 2-month period of 100 nM ATQ pressure. 
ATQ resistant parasites were also selected within 14-16 days with continuous 100 nM 
ATQ (Gassis & Rathod, 1996) and 10 nM ATQ pressure (Stickles et al., 2015b), 
respectively. Stickles et al. (2015b) recently reported the emergence of CYTb V259L 
ELQ-400 resistant parasites after 47 days under a continuous drug concentration of 100 
nM ELQ-400. Alternatively, our V259L mutants were not selected with T13 until 
parasites were exposed to continuous, increasing T13 pressure for 65 days, which 
occurred after the parasites had intermittent exposure to doses of T13 for an 81 day 
period. The M133I CYTb mutation, first reported by Korsinczky et al. (2000), was 
selected within 10 days using 20 nM ATQ pressure; however, it took 144 days to select 
M133I mutants with continuous T13 pressure. It is unknown why T13 has a longer period 
50#
of time to select resistant parasites with the same mutations as ATQ (M133I) (Korsinczky 
et al., 2000) and ELQ-400 (V259L) (Stickles et al., 2015b); however, this suggests that 
T13 does not readily select drug resistant parasites in vivo. We acknowledge that without 
a side-by-side comparison of selection rates with T13 and ATQ (or other CYTb 
inhibitors), as was performed by Stickles et al. (2015b) with ELQ400 and ATQ, it is 
difficult to determine the actual difference in time to select drug resistant parasites.  
We believe that T13 has a lower chance of selecting resistant parasites based on 
several possibilities. First, the binding affinity and chemical nature of each compound 
suggests there may be fewer mutational options for chemotype I acridones than ATQ. 
T13 may have a greater affinity to bind to CYTb than ATQ, resulting in an increased 
frequency for SNP selection in ATQ, or perhaps other SNPs may have been selected with 
T13 but lacked the fitness needed to survive in culture. To determine mutation frequency, 
side-by-side comparison of T13 and ATQ should be performed, as mentioned earlier, 
along with continuing T13 pressure on acridone resistant parasites in attempt to select 
more mutants, as was performed by Korsinczky et al. (2000) with ATQ. Secondly, 
secondary targets may slow down the rate of resistance; however this has not been 
determined with T13. To resolve this, future studies with yeast DHODH transgenic 
parasites tested against T13 may elucidate other T13 targets outside of cytb, similar to 
studies by Painter et al. (2007) demonstrating that ATQ apparently only targets Complex 
III in the ETC and is not an effective antimalarial if the critical function of this pathway 
(pyrimidine synthesis) is removed.   
To determine if T13 resistance could be selected in P. falciparum parasites with 
different genetic backgrounds than Dd2, CQS line 3D7 and CQR line 7G8 from Africa 
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and Brazil (Wootton et al., 2002), respectively, are currently being pressured with 
increasing, continuous T13 pressure. Resistance was recently selected in 3D7, exhibiting 
a 42-fold shift in T13 IC50 after 155 days of continuous T13 pressure (data not shown). 
Dd2 and 3D7 genetic backgrounds appear favorable in acquiring cytb mutations while 
7G8 may have a lower frequency of acquiring resistance; however, this relationship must 
be further investigated. We note that pressuring the 7G8 line with the antiviral 
amantadine for over a year did not produce detectable changes in drug phenotypes (R. 
Cooper, unpublished observations). The period of time it took to select (or not select) T13 
resistance in all three parasite lines was longer than the time to select ATQ and ELQ-400 
resistance; therefore suggesting T13 resistance is harder to select, irrespective of parasite 
genetic background. 
Genome Sequencing and SNPs Identified in T13 Resistant Parasites 
Mutations in genes such as pfcrt, pfatp4, and cytb provide a resource for drug 
target identification of multiple antimalarials by revealing molecular marker(s) of 
resistance in P. falciparum (Wellems & Plowe, 2001; Rottmann et al., 2010; Korsinczky 
et al., 2000). Polymorphisms acquired in the QO site of P. falciparum CYTb, specifically 
M133I and Y268S (Y268C/N also observed), exhibit a 25-fold and 9,354-fold decrease in 
ATQ susceptibility, respectively (Korsinczky et al., 2000). Research on mitochondrial 
beef heart extracts and the photosynthetic bacterium Rhodospirillum rubrum showed that 
acridones target Complex III of the ETC, specifically in the QO site of CYTb (Oettmeier 
et al., 1994a, 1994b); however, an acridone target had not been identified in Plasmodium 
spp. Winter et al. (2006) was the first to propose that alkoxy acridones (chemotype I) 
target the malarial CYTb protein due to the structural similarity of their side chain to the 
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experimental drug floxacrine, which has slight cross-resistance with ATQ (Suswam et al., 
2001). Winter et al. (2006) also proposed CYTb as the target of alkoxy acridones because 
of their structural similarity to ubiquinone, specifically, the long, flexible side chains 
characteristic of both molecules. Observation of the chemical structure of chemotype I 
acridones we tested, most notably T19 and T31, show the structural similarity of 
acridones to ubiquinone (Appendix III). 
Our work is the first direct evidence of acridones targeting CYTb in P. 
falciparum, thus validating the previous theories proposed for alkoxy acridones (Winter 
et al., 2006). Whole genome sequencing of Dd2-T13 resistant parasites identified a G to 
T mutation at cytb nucleotide 775, resulting in an amino acid change from V(GTA) to L (TTA) 
at position 259 next to the highly conserved “pewy” loop in the QO site (Figures 11 and 
14). The elevated T13 IC50 value in the V259L cytb mutants suggests that position 259 in 
CYTb may be a putative contact residue for T13. The V259L mutation explains the slight 
cross-resistance observed with QO site targeting ATQ and ELQ-400. We note that our 
V259L CYTb mutation differs from mutations acquired in ATQ resistant P. falciparum, 
but is the same mutation recently reported in ELQ-400 resistant parasites (Siregar et al., 
2014; Stickles et al., 2015b). The V to L mutation is a conservative chemical change, 
where the mutation maintained a nonpolar, hydrophobic amino acid; however, the change 
resulted in an additional carbon on the functional side chain. The M133I mutation 
previously reported in ATQ resistant parasites (Korsinczky et al., 2000) also maintained 
hydrophobicity and remained nonpolar; however, the amino acid change was significant, 
where the straight side chain containing sulfur was replaced with a branched carbon 
chain. 
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The structure of cytb is highly conserved across eukaryotic species (Berry, 2000). 
The P. falciparum cytb sequence was aligned to chicken and bovine mitochondrial DNA 
in multiple studies on ATQ resistance, most notably in the report by Korsinczky et al. 
(2000), showing that the cytb gene sequence is highly conserved across eukaryotic 
species. Molecular and biochemical characterization of the effect of ATQ on ATQ 
resistant mutants has been studied in a variety of model organisms such as the yeast 
Saccharomyces cervisiae (Kessl et al., 2003; 2005), bovine (Kessl et al., 2007), and 
Rhodobacter capsulatus bacterial system (Mather et al., 2005). Studies by both groups 
demonstrated the cytb sequences use as a model system for Plasmodium given the high 
conservation of this gene, therefore allowing them to describe the binding of ATQ to the 
ubiquinol binding site (QO) and interactions with the Reiske iron-sulfur protein (ISP). By 
utilizing the model systems, Kessl et al. (2003; 2005; 2007) and Mather et al. (2005) 
were able to understand the molecular basis of ATQ resistance and provide further 
insight into the mode of action of ATQ. 
ATQ is a competitive inhibitor of the ubiquinol oxidation pocket (Kessl et al., 
2003). The naphthoquinone binds where it interacts with the ISP complex by aromatic 
combinations and hydrogen bonding that mimic binding determinants seen with 
ubiquinol. ATQ fixes the conformation of the ISP, thus preventing complete hydrogen 
bonding and immobilizing the ISP structure from docking into the QO site (Mather et al., 
2005; Esser et al., 2006), specifically at positions 275 and 278 on CYTb, which are 
proposed to be key residues in ligand binding of the ISP and QO site (Kessl et al., 2003; 
2005). Possible disruption of the ef loop and protein structure surrounding the QO site by 
the V259L mutation may have caused instability of the ISP in the cytb mutants, thus 
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weakening hydrogen bonding and creating a greater binding distance, or displacement of 
the ISP and QO site (Esser et al., 2006; Xia et al., 2013). This process, in turn, halts work 
by DHODH and collapses the mitochondrial membrane potential by preventing electron 
transfer between the ISP and QO site (Barton et al., 2010). The M133I and novel V259L 
and A138T mutations have revealed the binding site of chemotype I acridones within the 
ubiquinol oxidation site. The V259L and A138T mutations identified will contribute to 
better understanding the ATQ binding site considering that the mutations are mapped to 
the same region as identified ATQ mutations. Furthermore, our work may also contribute 
to understanding the method by which other ETC targeting antimalarials bind to cytb in 
P. falciparum.  
The rare event of a valine to leucine amino acid change has also been investigated 
in human models. Liu et al. (2003) studied the effect of a valine to leucine mutation at 
residue 382 in cytochrome P450 1A1, an oxidase enzyme that plays a critical role in drug 
and toxicant metabolism and activation (hydrocarbons), while characterizing substrate 
binding of alkoxyresorufin derivatives to 1A1. V382 is postulated to interact with the 
alkoxy side chain of the resorufin substrates; therefore, this residue was identified as an 
important factor in p450 1A1 activity for docking enzyme substrates to the active site. 
Liu et al. (2003) found that the leucine in the V382L mutant blocked the alkoxyresorufins 
from proper binding orientation, thus leading to lowered enzyme activity and drastically 
affecting positioning of the alkoxyresorufin substrates to the active site by creating an 
unfavorable distance between the oxidation site hydrogen of resorufins and the ferryl 
oxygen. Moreover, the effect of the CYTb V259L mutation in our parasites most likely 
results in a conformational change that reduced the binding affinity of chemotype I 
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acridone T13 to the QO site, therefore allowing the parasites harboring the V259L 
mutation to evade membrane potential collapse and provide continual function of 
DHODH. Changes in the binding affinity that affect the transfer of electrons from the QO 
site to the ISP have been reported in other QO site inhibitors such as ATQ, famoxadone, 
and stigmatellin (Kessl et al., 2003; Esser et al., 2006; Berry et al., 2011). 
Although CYTb was the proposed target of chemotype I acridones (Winter et al., 
2006), it was never demonstrated in Plasmodium spp. Therefore, we performed whole 
genome sequencing on the originally selected T13-resistant parasites to determine all 
possible markers of T13 resistance. Out of the 14 nonsynonymous SNPs identified 
outside of cytb, 8 of the SNPs were in either highly polymorphic var genes or in proteins 
of unknown function (Table 2); therefore, they were not looked at further. Four of the 
SNPs with identifiable locations (methyltransferase, protein kinase, AP2 domain, and 
dynein heavy chain), were not further studied as the nucleotide mutation differed from 
Dd2, but matched the 3D7 reference strain. The 2 remaining SNPs that differed from both 
3D7 and Dd2 reference strains were found in a transcription factor in the AP2 domain 
(ApiAP2) and in a putative RNA helicase. It is unknown whether these mutations are 
contributory; consequently, the investigation of the ApiAP2 and RNA helicase SNPs 
identified from whole genome sequencing is a limitation of our study. However, Painter 
et al. (2010) suggested ApiAP2 proteins may serve as important transcription factors in 
parasite development while Tarique et al. (2013) stressed the importance of DEAD box 
RNA helicases and their critical role in RNA metabolism; therefore the mutations 
acquired in these two proteins in the T13 mutants may play an important role in parasite 
survival. Another limitation of the study is that the genome sequencing was performed on 
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two clones from only one independently selected resistant culture; therefore, further 
investigation with the remaining Dd2-T13V259L mutants is warranted to ascertain if the 
mutations outside of cytb are present in other independently selected T13 resistant 
parasites. To make full use of the genome sequencing results, we should perform targeted 
sequencing of the AP2 domain and of the RNA helicase sequence in all T13 mutants.  
The mutations identified in the cytb mutants provide a means for a more detailed 
analysis of acridone binding to CYTb in control vs. mutant parasites by molecular 
modeling and activity assays. Sequencing of the cytb gene in 3D7-T13 parasites 
identified the V259L mutation seen in Dd2-T13 parasites as well as a novel A(GCT) to 
T(ACT) mutation at amino acid position 82. The A82T mutation observed in the 3D7-T13 
mutants is the only mutation in cytb that does not lie within the QO regions. Therefore, we 
believe the mutation may play a compensatory role in parasite fitness rather than 
decreasing parasite susceptibility given the T13 IC50 has a similar value observed in Dd2-
T13V259L parasites. The identification of the M(GTA) 133 I(ATA) and A(GCA) 138 T(ACA) 
mutations in the cytb mutants selected during continuous pressure further strengthens our 
claim that chemotype I acridones target the QO site in CYTb, as well as shows that 
acridones have a similar target, and effect on the ETC, as ATQ. Identification of 
mutations in the QO site provides a resource for future studies on ETC targeting 
antimalarials and now provides direct evidence of chemotype I acridones target in P. 
falciparum.  
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INTERMEMBRANE SPACE 
 
MITOCHONDRIAL MATRIX 
Figure 14: Proposed target and mutations identified in the QO site of the ETC in T13-resistant parasites. 
pfmdr1 Copy Number and its Role in T13 Resistance 
pfmdr1 encodes for the pgh1 protein localized on the parasite DV, and is 
hypothesized to be responsible for the influx of solutes into the DV (Cowman, et al., 
1991; Rohrbach et al., 2006). Variation in pfmdr1 copy number can mediate resistance to 
multiple antimalarials with diverse targets and can even confer resistance to the 
antimalarial MEF (Price et al., 2004). Sidhu et al. (2006) confirmed the importance of 
pfmdr1 copy number in multifactorial resistance and cross-resistant patterns in the 
antimalarials LUM, QN, ART, and HF. They suggested other factors associated with 
resistance might be polymorphisms in pfmdr1 and discussed how increased copy number 
has resulted in increased drug susceptibility to LUM and QN in some studies, but not 
others. Amplification of pfmdr1 in the cytb mutants may also serve as a factor in acridone 
resistance.  
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We sought to identify whether pfmdr1 copy number played a role in T13 
resistance; therefore, we carried out a multiplex qPCR to look at this gene in the Dd2-
T13V259L cytb mutants. pfmdr1 copy number increased by a single copy in the cytb 
mutants tested, from 3 to 4 copies, when compared to wild-type Dd2 (3 copies). Dd2 
parasites are known to have 3-4 copies of pfmdr1 (Patel et al., 2010); therefore, the 
elevated number in pfmdr1 copies may not have been due to an amplification event, but 
rather, the parasites harboring 4 copies in wild-type Dd2 outcompeted the parasites with 3 
pfmdr1 copies; however, the mixed copies (3-4) observed in the cytb mutants indicates 
that one did not outcompete the other. Long-term studies would have to be performed 
with the cytb mutants to understand if it is advantageous to harbor 4 copies of pfmdr1. 
Although it appears CYTb is the main target of T13 and the major cause for T13 
resistance, elevated pfmdr1 copy number may play a minor role in decreased T13 
susceptibility or may compensate for the fitness cost of acquired resistance. Future work 
should be performed on all cytb mutants harboring mutations selected with T13 to see if 
there is a change in pfmdr1 copies. 
Structure Activity Relationship of Chemotype I Acridones 
In-depth structure activity relationship (SAR) analysis will help elucidate the 
binding relationship of chemotype I acridones with CYTb by analyzing cross-resistance 
patterns in Dd2-T13V259L cytb mutant parasites. We have identified varying levels of 
cross-resistance from a 2.8-26 fold increase in IC50 in a panel of 13 chemotype I 
acridones. No cross-resistance was observed with T2.2, which was the only chemotype I 
acridone tested with an alkoxy side chain at the 7th position, instead of the 6th position, of 
the acridone core (Appendix III). The lack of cross-resistance with T2.2 suggests there is 
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a second chemotype I acridone target, or that T2.2 interacts differently with CYTb where 
it is able to evade cross-resistance. It also suggests that T2.2 could be used in antimalarial 
treatment where there would be no concern for cross-resistance with ATQ, ELQ-400 or 
the other chemotype I acridones tested.  
The Dd2-T13V259L cytb mutants varying degrees of cross-resistance seen with the 
other 11 chemotype I analogs prompted us to examine their structures in greater detail. 
The highest levels of cross-resistance were obtained with T2, T26, and T27, implying the 
CYTb QO site is also the main target for these three acridones. The fluorine (F) and 
chlorine (Cl) substituents at positions 1 and 3 of T26 and T27 (Appendix III), 
respectively, may not be optimal placement for preventing cross-resistance. Winter et al. 
(2006) reported that placement of a highly electronegative nitro group as the electron 
withdrawing substituent resulted in a significant decrease in antimalarial activity of 
alkoxy acridones, whereas, reduction of the nitro group to an amine caused a dramatic 
increase in antimalarial potency. This may also be the case in the effect of the highly 
electronegative fluorine on the cytb mutants, where a high level of cross-resistance was 
observed in the V259L cytb mutant.  
Alternatively, the Cl substituent at the 1st position on T2 does not appear to play a 
role in cross-resistance considering the substituent is in the same position on T2.2, which 
has no cross-resistance to T13. T14 was the only chemotype I analog with the same side 
chain as T13 that exhibited a mild degree of cross-resistance. The mild degree of cross-
resistance may result from the placement of the Cl substituents at the 2nd and 3rd positions, 
unlike T13, where the two chlorines are on the 1st and 2nd positions of the acridone. T19, 
T20, T31 and T13M, with the Cl substituents in the 1st and 2nd positions (same as T13) on 
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the acridone core, have a minor shift in IC50 from 2.8-10 fold (Table 3; Appendix III). 
The low degree of cross-resistance in these four analogs may be due to the differing side 
chains at the 7th position. The side chain on T31 is the most similar to T13 between these 
four analogs, which may have caused the highest shift in susceptibility from this group. 
Lastly, the 25-fold shift in susceptibility of analog T17 may be the result of the structural 
similarity of its side chain to T13, except terminating with a Cl, which may not be 
optimal for evading cross-resistance with T13; however, further testing must be 
performed with other terminal Cl analogs to determine if this statement is true. The lack 
of cross-resistance observed with chemotype II acridones T16.5 and T26.5 indicate that 
chemotype I and II acridones do not share the same drug target. Chemotype II acridones 
target the P. falciparum digestive vacuole; therefore, the digestive vacuole is most likely 
not a target of T13. Our studies on SAR with chemotype I and II acridones provide 
insight as to which acridones may have similar or identical target interactions as T13. The 
varying degrees of cross-resistance indicate which compounds may need to be further 
optimized to prevent cross-resistance or reduce the degree of resistance.  
Cross-resistance of T13 with Common Antimalarials 
Multiple types of antimalarials exhibit cross-resistance because of having the 
same or similar targets within the malaria parasite (Johnson et al., 2004; Sidhu et al., 
2006; Cooper et al., 2002 & 2007). CQ and AQ have varying degrees of cross-resistance 
because of mutations in pfcrt and pfmdr1, especially K76T and N86Y, respectively 
(Holmgren et al., 2006; Sá et al., 2007). Identifying antimalarial cross-resistance patterns 
not only aids in drug target discovery, such as identifying cytb as a chemotype I acridone 
target based on cross-resistance with ATQ, but it provides insight as to which 
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antimalarial therapies would be best suited in regions of the world where a drug may be 
rendered ineffective. Therefore, we tested the cytb mutants against an array of 
antimalarials with diverse drug targets with the goal of identifying to which, if any, 
antimalarials the mutant parasites may have also acquired resistance.  
Winter et al. (2006) suggested that acridones target P. falciparum Complex III of 
the ETC; therefore, the Dd2-T13V259L, Dd2-T13M133I, and Dd2-T13M133I+A138T lines were 
also tested for altered susceptibility to the antimalarials ATQ and ELQ-400, which target 
CYTb (Vaidya & Mather, 2009; Siregar et al., 2014; Stickles et al., 2015b). Cross-
resistance was observed in only ATQ and ELQ-400, while the susceptibility of all other 
antimalarials remained unchanged. The V259L mutation resulted in only a 10-fold shift 
in ELQ-400 IC50, unlike the 36-38 fold shift this mutation imparted on T13, indicating 
that position 259 is most likely a central location in CYTb where T13 binds, but not 
ELQ-400. To note, the 10-fold shift observed with ELQ-400 and ATQ susceptibility in 
V259L mutants agrees with V259L data reported by Stickles et al. (2015b). The G to A 
mutation at nucleotide 399 (M133I) lying within QO site region 1 conferred a 16-18 fold 
increase in ATQ, agreeing with previous reports about the M133I mutation and 
susceptibility to ATQ (Korsinczky et al., 2000). The 6-fold shift in T13 susceptibility 
accompanied by the M133I mutation supports the argument that ATQ and T13 share a 
similar drug target in CYTb (Winter et al., 2006). The increased sensitivity to ELQ-400 
in parasites with the M133I mutation implies that this mutation augments parasite 
susceptibility to ELQ-400. Surprisingly, the same effect was seen with ATQ in the Dd2-
T13M133I+A138T parasites after the acquisition of the A138T mutation, suggesting this 
mutation increases ATQ susceptibility. Similar work by Sidhu et al. (2005) found an 
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inverse relationship where an N1042D mutation in pfmdr1 enhanced MEF, ART and HF 
sensitivity while contributing to QN and QD resistance. The cross-resistance observed 
with only ATQ and ELQ-400 suggests that CYTb is the major target of chemotype I 
acridones, and that all three drugs share a common binding site in CYTb. Therefore, if 
chemotype I compounds will be used in the clinical setting, it may not be ideal to use in 
areas where high-level ATQ resistance is observed. 
Currently, there are limited drug targets in P. falciparum; therefore, it is common 
for multiple, chemically distinct antimalarials to target the same location. Antimalarials 
such as CQ or MEF will select for drug resistant parasites when used as a monotherapy 
(Payne, 1987; Smrkovski et al., 1982), initiating the need for combination therapy 
(Nosten & White, 2007). ATQ, a CYTb inhibitor, will never be used as a monotherapy as 
it rapidly selects for drug resistant parasites (Looareesuwan et al., 1996); however, when 
used in combination with proguanil, such as in Malarone, the treatment is highly 
effective, with a 98% success rate, and few reports of treatment failure (Wurtz et al., 
2012; Plucinski et al., 2014). Presently, many antimalarials are being developed that 
target locations in P. falciparum where resistance has already been selected. Highly 
potent endochin-like quinolones show that they can select drug resistance, however the 
drugs still remain potent (Stickles et al., 2015b). Seemingly, no matter where the target, 
resistance will be selected; therefore, combination therapy is key to protecting 
antimalarials from becoming ineffective.  
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Ex vivo Studies of Chemotype I Compounds in Clinical P. falciparum Isolates 
Ex vivo assays provide a non-invasive method of testing antimalarial potency 
against parasites taken directly from the clinical setting. Although the testing is not within 
malaria-infected humans, the data obtained provides insight on drug susceptibility in 
parasites that have not become culture adapted. In an attempt to monitor drug 
susceptibility in Burkina Faso, Tinto et al. (2014) carried out ex vivo studies with 440 
malaria-infected patient blood samples 5 years after the implementation of ACT 
treatment. From the six drugs tested by IC50 (CQ, QN, DHA, LUM, 
monodesethylamodiaquine and PIP), they were able to determine the continual efficacy 
of artemisinin derivatives while there was a worrisome decline in parasite susceptibility 
to LUM. Tinto et al. (2014) concluded that ACT treatment with DHA-PIP was still 
highly effective treatment while the treatment with artemether-LUM should be monitored 
more closely in this region; therefore, they were able to establish that the potency of 
artemisinins and PIP were unchanged. The potency of chemotype I acridones was 
determined for analogs T13, T31, and T35 against parasite isolates collected directly 
from Ugandan children in 2012. The results were consistent with their in vitro potency 
against lab-adapted lines. The in vitro and ex vivo potency of several chemotype I 
acridones, such as T31 and T35, have comparable IC50 values to highly potent 
antimalarials in current clinical treatment or prophylaxis, such as LUM (Dd2 IC50 = 5.7 ± 
0.21) and ATQ (Dd2 IC50 = 0.50 ± 0.043). The data shows that clinical isolates are highly 
sensitive to chemotype I acridones; therefore, there is no observed resistance in the 
clinical setting and the compounds may serve as effective chemotherapeutics in malaria 
endemic countries. 
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The Effect of CYTb V259L Mutation on Parasite Growth 
The fitness of resistant parasites is based on the comparison of growth rates by 
utilizing competitive growth experiments. Mutations in drug resistant parasites come at a 
fitness cost (Rosenthal, 2013). However, compensatory mutations may improve fitness 
for resistant parasites, thus allowing survival without drug pressure or even during 
competitive growth experiments (Rosenthal, 2013). IC50 assays, performed after the final 
day of the competition assay, and mutation-specific qPCR results indicate that the V259L 
cytb mutants were more fit than Dd2 in mixed cultures. Fitness consequences with 
acquired drug resistance in Plasmodium spp. are studied in vitro, in animal models, and 
in clinical studies. Previous studies performed on parasites harboring high-level 
resistance to antifolates had increased copy number of the gene GTP-cyclohydrolase 1 
(gch1) that accompanied the dihydrofolate reductase (dhfr) I164L mutation (Nair et al., 
2008). The combination of the two made the mutant parasites more fit than the parasites 
that did not have the I164L mutation accompany the elevated gch1 copy number. If the 
compensatory change is a similar fitness advantage mechanism in the V259L cytb 
mutants, but with elevated pfmdr1 copy number or a SNP in another gene as a 
compensatory adaptation, then there would appear to be no cost of fitness in the T13-
resistant parasites.  
Genome sequencing of the V259L CYTb mutants revealed 14 SNPs outside of 
cytb. It remains unknown whether 6 of the SNPs identified serve a role in parasite fitness 
considering the mutations are in proteins of unknown function. Two of the SNPs 
identified are located in highly polymorphic var genes, thus were not considered to serve 
as a fitness advantage. However, a SNP identified in transcription factor proteins ApiAP2 
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and in an RNA helicase may shed light on the acquired fitness advantage. To determine 
whether the V259L mutants continually outcompete wild-type parasites, other V259L 
mutants need to undergo the competition assay experiment. Transfection studies should 
also be performed to determine if the V259L mutation confers the fitness advantage or if 
one of the 14 SNPs identified by genome sequencing (or pfmdr1 copy number) is 
responsible. Transfection studies by Painter et al. (2007) that replaced PfDHODH with 
the yeast enzyme (yDHODH), thus functionally removing the need for CYTb to 
regenerate ubiquinone, revealed that ATQ was not effective without the presence of 
functional CYTb.  
Use of the yDHODH-transgenic parasites (Painter et al. 2007), along with our 
competition assay, will reveal if the V259L mutation is the sole contributor to T13 cytb 
mutant fitness. The yDHODH parasites could serve as a control in transfection studies 
with V259L mutants to show that parasites with a nonfunctional ETC, and alternative 
pathway for pyrimidine synthesis, are fit in culture when cytb is the sole contributor to 
resistance. Replacing the Plasmodium DHODH in the V259L mutants with yDHODH, or 
transfecting the V259L mutation into a wild-type Dd2 lacking the SNPs identified outside 
of cytb will reveal whether the V259L mutation confers the fitness advantage or if the 
improved parasite fitness is multigenic. To observe the effect of the transfected T13 
mutant parasite growth, the parasites would be placed into the competition assay against 
Dd2 or yDHODH. Highly fit parasites in vitro may reflect how well the parasites will 
survive in the clinical setting; however, the SNPs selected in vitro may not reflect what 
mutations will be observed in clinical isolates. 
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Conclusion: 
The emergence of drug resistance is a continuous threat to antimalarials, old and 
new. Therefore, the need for antimalarial drugs that can circumvent this event is of great 
urgency. The P. falciparum mitochondrial electron transport chain, specifically the 
cytochrome bc1 complex, is an attractive target for drug design due to the undeniable 
necessity for the biosynthesis of pyrimidines. 
Antimalarial acridones show potential in the treatment of malaria. Not only do 
they have intrinsic antimalarial potency and liver targeting ability (chemotype I), but 
chemosensitizing capabilities as well (chemotype II). We successfully selected P. 
falciparum parasites resistant to dual stage chemotype I acridones and have identified a 
V259L mutation within the QO site of CYTb, recently seen in ELQ-400 resistant 
parasites, as well as an M133I mutation seen in ATQ resistant parasites. We have also 
identified novel A to T mutations at positions 138 and 82 in CYTb. We can infer that the 
mitochondrial ETC CYTb protein is likely the main target of chemotype I acridones. 
Further investigation to validate the resistance acquired in our mutant parasites as well as 
the possible identification of more or all factors attributed to the mechanism of action of 
chemotype I acridones will need to be performed. Identification of T13 resistance 
determinants in the in vitro selected lines will provide a resource for studies into the 
pathways that may mediate chemotype I resistance in the clinical setting. 
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APPENDICES 
APPENDIX I: ABBREVIATIONS 
3D7: Chloroquine sensitive parasite harboring a single copy of pfmdr1 
7G8: Chloroquine resistant parasite 
ACT: Artemisinin-based combination therapy 
ATQ: Atovaquone 
AQ: Amodiaquine 
Complex III: cytochrome bc1 complex of the electron transport chain 
CQ: Chloroquine 
CQR: Chloroquine Resistant 
CQS: Chloroquine Sensitive  
CYTb: cytochrome b protein 
cytb: cytochrome b gene 
Dd2: Chloroquine resistant parasite harboring 3-4 copies of pfmdr1 
Dd2-T13: T13 resistant selected parasites  
DHA: Dihydroartemisinin  
DHODH: dihydroorotate dehydrogenase 
DV: digestive vacuole 
ELQ: endochin-like quinolone 
ETC: Electron Transport Chain 
h: Hour 
I: Isoleucine 
IC50: Concentration of drug that inhibits 50% of parasite growth 
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APPENDIX I: ABBREVIATIONS 
ISP: Iron-sulfur protein; transfers electrons from CYTb to CYTc 
K: Lysine 
L: Leucine 
LUM: Lumefantrine 
M: Methionine 
MEF: Mefloquine 
nM: nanomolar 
pfcrt: Plasmodium falciparum Chloroquine Resistance Transporter gene 
PFCRT: Plasmodium falciparum Chloroquine Resistance Transporter protein 
PFMDR1: Plasmodium falciparum Multi-drug Resistance Protein 1 
pfmdr1: Plasmodium falciparum Multi-drug Resistance gene 
PIP: Piperaquine 
QC: Quinacrine 
QN: Quinine 
QO site: ubiquinol oxidation site 
SNP: Single Nucleotide Polymorphism 
T: Threonine 
T13: Chemotype I acridone analog 
T2.2: Chemotype I acridone analog 
T16.5: Chemotype II acridone analog 
V: Valine 
WHO: World Health Organization 
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APPENDIX II: P. falciparum Laboratory Strains  
 
Isolate Origin CQ Sensitivity ATQ Sensitivity pfmdr1 CN 
Dd2 Indochina CQR ATQ-S 2-4 
7G8 Brazil CQR ATQ-S 1 
3D7 Africa CQR ATQ-S 1 
 
CN: copy number 
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APPENDIX III: Drug Classes and Structures  
Class Drug Structure 
4-aminoquinoline CQ 
 
Hydroxynapthoquinone ATQ 
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Chemotype I Acridone T20 
 
 T22 
 
 T26 
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Chemotype II Acridone T16.5 
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APPENDIX IV: Drug Susceptibilities of Cloned Dd2-T13 Mutants 
 
Drug susceptibility results of cloned P. falciparum Dd2-T13 mutants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 values ± SEM in nM. N ≥ 3. 72 h Microplate test using Sybr Green detection. 
Dd2-T13a underwent 24-hour and continuous pressure, with resistance selected after continuous pressure. Dd2-T13b-c underwent 24-hour and 
continuous pressure. Resistance selected during on-off pressure. Dd2-T13d underwent continuous pressure.  
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.0001 [****] 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.001 [***] 
Two-tailed t-test of average IC50 of mutant vs. Dd2 control where p < 0.01, p < 0.05 [**]
Drug Dd2 
Dd2-T13 Resistant Mutants; IC50 ± SEM (nM) 
T13aF1  T13bH9  T13cD3  T13dE4 T13dF5 
CQ 181 ± 4.3 166 ± 7.1 185 ± 4.4 231 ± 11 182 ± 5.6 186 ± 8.0 
QN 254 ± 9.8 215 ± 7.5 317 ± 20 254 ± 16 197 ± 3.5 199 ± 13 
MEF 18 ± 1.3 23 ± 0.95 21 ± 1.9 21 ± 2.3 14 ± 0.71 13 ± 0.61 
LUM 5.7 ± 0.21 6.5 ± 0.32 6.4 ± 2.3 6.4 ± 0.53 3.6 ± 0.19 3.6 ± 0.26 
PIP 9.0 ± 0.17 7.1 ± 0.25 11 ± 0.58 9.0 ± 0.31 10 ± 0.31 7.4 ± 0.27 
ATQ 0.43 ± 0.038 3.8 ± 0.26**** 3.7 ± 0.27*** 2.8 ± 0.17** 6.9 ± 0.95**** 1.4 ± 0.052** 
T13 40 ± 5.5 1439 ± 49**** 1578 ± 79 **** 1528 ± 70**** 242 ± 18** 1678 ± 78**** 
QC 29 ± 1.3 18 ± 0.74* 29 ± 1.5 29 ± 1.8 23 ± 0.59 29 ± .67 
ELQ-400 3.4 ± 0.11 33 ± 2.2*** 24 ± 0.91*** 39 ± 1.7*** 0.72 ± 0.035 3.1 ± 0.14 
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APPENDIX V: qPCR Primers and Conditions for pfmdr1 Copy Number Analysis 
 
Primers Sequence 5’ end  3’ end  
pfmdr1–1F 5’-TGCATCTATAAAACGATCAGACAAA   
pfmdr1–1R 5’-TCGTGTGTTCCATGTGACTGT   
pfmdr1–probe 5’-TTTAATAACCCTGATCGAAATGGAACCTTTG FAM TAMRA 
β-tubulin-1F 5’-TGATGTGCGCAAGTGATCC   
β-tubulin-1R 5’-TCCTTTGTGGACATTCTTCCTC   
β-tubulin-probe 5’-TAGCACATGCCGTTAAATATCTTCCATGTCT VIC TAMRA 
 
 
PCR Amplification Protocol 
Temperature Time (seconds) Cycles 
95°C 20 40 
95°C 1 40 
60˚C 20 40 
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APPENDIX V: qPCR Primers and Conditions for pfmdr1 Copy Number Analysis 
 
 
qPCR Sample Volumes for pfmdr1 Copy Number Analysis 
 [Final] Volume (μL) Multiple Total (μL) 
Taqman Mastermix (2X) 1X 12.5  1200 
H2O  6.5 100 1015 
MDR_F 100uM 0.3 uM 0.75 100 7.5 
MDR_R 100uM 0.3 uM 0.75 100 7.5 
βtubulin_F 100uM 0.3 uM 0.75 100 7.5 
βtubulin_R 100uM 0.3 uM 0.75 100 7.5 
MDR_pB 100uM 0.1 uM 0.25 100 2.5 
βtubulin_pB 100uM 0.1 uM 0.25 100 2.5 
TOTAL ---- 22.5 100 2250 
DNA per well ~2 ng/μL 2.5 4 10 
TOTAL PER WELL ---- 25   
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APPENDIX VI: PCR Primers and Conditions for Sanger Sequencing of cytb 
Primers used for Sanger sequencing of cytb. 
Primers Sequence Start Stop Tm 
cytb-F 5’-TTCCTGATTATCCAGACGCT 3380 3399 53.2 
cytb-R internal 5’-CACTCACAGTATATCCTCCACA 3978 3957 53.5 
cytb-F internal 5’-GAGTTATTGGGGTGCAACTG 3890 3909 53.8 
cytb-R  5’-TGTTCCGCTCAATACTCAGA 4670 4651 53.3 
 
 
PCR Amplification Protocol 
Temperature Time  Cycles 
95°C 2 minutes Pre-read stage 
95°C 30 seconds 30 
42°C 1 minute 30 
65°C 2 minutes 30 
 
 
PCR Sample Volumes  
 [Final] Volume (μL) 
MeanGreen Taq Master mix (2X) 1X 25 
H2O  18 
Forward Primer 0.2 μM 1 
Reverse Primer 0.2 μM 1 
TOTAL ---- 45 
DNA per well ~10 ng/μL 5 
TOTAL PER WELL ---- 50 
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APPENDIX VII: PCR Primers and Conditions for SNP Genotyping 
 
Primers Sequence 5’ end 3’ end Tm 
cytb-F 5’-TCACATCCTGATAATGCTATCGTAGT ---- ---- 57 
cytb-R 5’-GCTGGTTTACTTGGAACAGTTTTTAA ---- ---- 58 
cytb-probe 5’-CATCTCAAATTGTACCTGAA VIC MGB 67 
cytbT13-probe 5’-TACTCCATCTCAAATTTTACCT FAM MGB 67 
 
 
PCR Amplification Protocol 
Temperature Time (seconds) Cycles 
60°C 30 Pre-read stage 
95°C 10 minutes Hold stage 
95°C 15 40 
60°C 1 40 
60˚C 30 40 
 
 
qPCR Sample Volumes for SNP Genotyping for Competition Assay 
 [Final] Volume (μL) Multiple Total (μL) 
Taqman Mastermix (2X) 1X 10  1000 
H2O  7 100 700 
SNP Assay Mix (20X) 1X 1 100 100 
TOTAL ---- 18 100 1800 
DNA per well ~10 ng/uL 2 4 8 
TOTAL PER WELL ---- 20   
 
